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Abstract
HSV-1 and HIV-1 co-infection of human macrophages represents a clinically relevant model
with which to investigate the host-pathogen interactions between macrophages and viruses. In this
thesis, I demonstrate that HSV-1 productively infects human monocyte derived macrophages, with
associated cell death and type I IFN responses, and additionally, that a proportion of macrophages
support latent HSV-1 infection. I define latency as the absence of lytic gene transcription, virion
production and cell death, in the presence of persistent expression of the HSV-1 latency associated
transcript (LAT). I also demonstrate that HSV-1 super-infection increases HIV-1 transcription,
and that latent HSV-1 can be reactivated by HIV-1. HSV-1 latent infection of neurons is well
established, but this is the first report, to my knowledge, of HSV-1 latent infection of myeloid
lineage cells. The potential for macrophage reservoirs of latent HSV-1 may be an important factor
for the clinical management of persistent reactive HSV-1 disease. Furthermore, HIV-1 infection
in vivo is known to increase the frequency of HSV-1 reactivation in the host through the indirect
mechanism of immune system suppression. However, a direct interaction between cells latently
infected with HSV and HIV-1 has not previously been observed. Reactivation of latent HSV by
HIV-1 therefore provides a novel mechanism for the well-established clinical synergy between these
viruses.
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1 Introduction
1.1 Aims
In this thesis I aim to characterize herpes simplex virus-1 (HSV-1) and human immunodeficiency virus-
1 (HIV-1) co-infection of human macrophages. Cellular responses to viral infection are highly cell-
type, species and pathogen specific (1–4). Consequently, to fully understand the host response to virus
infection, research using an infection model of a clinically relevant pathogen and cell-type is essential.
Macrophages are important cells of the innate immune system and can be infected by both HIV-1 and
HSV-1 (5–9). From a clinical perspective, macrophages are important cellular reservoirs of HIV-1 infection
and are present at HSV-1 lesions (9–13). Furthermore, HSV-1 and HIV-1 interact at both the clinical
and epidemiological level (14,15). Therefore, HSV-1 and HIV-1 co-infection of human macrophages
represents a clinically relevant model with which to investigate the host-pathogen interactions between
macrophages and viruses, and the potential interactions of HIV-1 and HSV-1 at the cellular level.
1.2 Summary
In this introduction I outline the scientific literature regarding macrophages, innate immune responses,
HSV-1 and HIV-1. I describe the cellular immunology of macrophages; the principles of the innate
immune response to viruses, including pathogen detection, type I interferon (IFN) responses and cell
death; basic HSV-1 and HIV-1 virology and the interactions of HSV-1 and HIV-1 with the innate
immune system, macrophages and each other.
1.3 Macrophages
The innate immune system is the first line of defence against infection (16). Components of innate
immunity detect infection, mount rapid inflammatory and antiviral responses and orchestrate adaptive
immunity (17,18). Macrophages are important cells of the innate immune system. They are tissue resident
sentinels (5,6) responsible for eliciting cellular defence mechanisms and recruiting and activating compo-
nents of adaptive immunity (7). They are also target cells for a variety of intracellular pathogens including
HIV-1 (8,9), Mycobacteria tuberculosis (19), Leishmania (20) and human cytomegalovirus (HCMV) (21).
Macrophage phenotypes are diverse and tissue specific (5), ranging from the Kupffer cells of the liver (22)
to the microglial of the brain (23). Macrophages also alter their phenotype in response to inflammatory
stimuli (24–26). Transcriptome analysis has highlighted the diversity of transcriptional states macrophages
occupy, a diversity that mirrors the signals that they receive (25,27,28).
Macrophages, along with dendritic cells (DCs) and Langerhan cells (LC), are part of the mononuclear
phagocyte system (MPS). Traditionally, macrophages were thought to be derived from a temporal series
of progenitor cells produced in turn by the yolk sac, fetal liver and bone marrow (BM) (29). The BM
produces circulating monocytes that differentiate into macrophages within the tissue (30). However,
there is now evidence suggesting that, at least in mice, the majority of tissue macrophages are derived
from the yolk sac (31). The BM produces circulating monocytic progenitors that differentiate into either
DCs or macrophages in the tissue, and it is only these macrophages that are replaced, whereas yolk
sac derived macrophages persist throughout life (32). However, it is not known which, if either, of these
models correspond to human macrophage ontology.
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Primary macrophages can be extracted from tissue (19). However, these macrophages are subjected to
significant stress that may alter their phenotype so it is unclear how closely they resemble macrophages in
vivo (5,19). In the tissue, infiltrating monocytes are exposed to a spectrum of growth factors that induce
differentiation into macrophages (33). Monocytes from the peripheral blood can be differentiated in vitro
into tissue macrophage-like cells using growth factors such as macrophage colony-stimulating factor (M-
CSF) and/or granulocyte macrophage colony-stimulating factor (GM-CSF) (9). The phenotype of the
resulting macrophages is dependent on the growth factor(s) used. Indeed, M-CSF and GM-CSF bind
different receptors, use different downstream signalling pathways (26,33) and elicit differential responses
in cells of the MPS (34–36). Based upon cytokine expression, GM-CSF differentiated macrophages have
a pro-inflammatory phenotype whereas M-CSF differentiated macrophages have an anti-inflammatory
or ‘resting’ phenotype (26,28). M-CSF is produced in steady state whereas GM-CSF is an inflammatory
cytokine associated with IFN-γ production (37,38). Additionally, whereas M-CSF deficiency is associated
with a lack of macrophages, GM-CSF deficiency is associated with alveolar proteinosis but not necessarily
fewer macrophages (39). Taken together these data suggest that M-CSF is responsible for macrophage
differentiation and that GM-CSF modulates macrophage function (33,40).
1.4 Pattern recognition receptors
The innate immune system uses germ-line encoded receptors to detect invading pathogens (17). A broad
range of pathogen associated molecular patterns (PAMPs) are detected by these pattern recognition
receptors (PRRs), including components of bacterial and fungal cell walls, pathogen nucleic acids
and viral glycoproteins (41,42). Engagement of a PRR with its PAMP can lead to a broad range of
intracellular signalling events and cellular responses, including inflammatory cytokine release, induction
of a type I IFN response, establishment of an antiviral state, induction of programmed cell death and
post-translation responses such as inflammasome activation (43).
Macrophages express a broad array of PRRs able to detect viral infection (6). Many of these de-
tect intracellular foreign and inappropriately localised nucleic acids indicative of viral infection. These
PRRs include the endosomal toll-like receptors (TLRs) and cytostolic receptors from the retinoic acid-
inducible gene 1 like receptor (RLR) and PYHIN protein families. In particular, TLR3, 7 and 9 detect
double-stranded (ds)RNA, single-stranded (ss)RNA and cytosine and guanine rich DNA (CpG DNA)
respectively (44). The cytosolic RLR family members RNA sensors retinoic acid-inducible gene 1 (RIG-I)
and melanoma differentiation-associated protein 5 (Mda5), detect short 5’triphosphate (5’PPP) RNAs
and ssRNA respectively (45,46) (Fig.1). In addition, there are many cytosolic DNA sensors, including
Z-DNA binding protein-1 (ZBP-1) (47), absent in melanoma-2 (AIM2) (48), γ-interferon-inducible pro-
tein 16 (IFI16) (49) and the recently discovered cyclic GMP-AMP synthase (cGAS) (50). The PRRs that
detect nucleic acid are summarized in Table 1 and Figure 1.
Currently, it is unclear why there are so many sensors of cytoplasmic nucleic acid. It is likely that nucleic
acid sensors operate in both a cell and pathogen dependent manner. Consequently, investigating the
function of these sensors in a immunological relevant cell type, such as macrophages, may provide novel
insights into the specificity of their function. This is particularly the case for cells that are targets for
clinically important viruses such as HSV-1 and HIV-1.
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Ligation of a PRR can induce expression of type I IFN. IFNβ and IFNα transcription are dependent
on interferon regulatory factor (IRF)3 and/or IRF7 phosphorylation, dimerization, nuclear translocation
and binding to the IFNβ gene (ifnb) promoter (Fig.1). The signalling pathways leading to IRF3/IRF7
activation vary considerably (51,52), for example, TLR3 associates with TIR-domain-containing adapter-
inducing IFNβ (TRIF) (44), RIG-1 and Mda5 bind IFNβ promoter stimulator-1 (IPS-1) (53), leading to
the assembly of a signalling complex composed of TNF receptor associated factor (TRAF)-3, tank-
binding kinase-1 (TBK1) and inhibitor of NF-κB kinase (IKK)- (54,55), whilst cGAS produces atypical
cyclic guanosine (cGAMP), a secondary messenger that activates stimulator of IFN genes (STING) at
the mitrochondrial membrane (56). There is also considerable cross-talk between the signalling pathways
involved in induction of type I IFN expression, up-regulation of inflammatory cytokines and activation
of cell death signalling. NF-κB for example can be involved in all three of these processes (57), and is
necessary for ifnb transcription in some but not all contexts (58,59).
1.6 Type I IFN
Interferons are divided into type I and type II, and subdivided within these classes based on sequence
homology, molecular structure and receptor usage (60,61). The IFN classes are summarised in Table 2.
Type I IFNs are encoded by multiple ifna genes, one ifnb gene and the more recently identified , κ
type I IFN encoding genes (60,62).
Type I IFNs can be produced by almost any nucleated cell. Following its release, IFN-β binds the
heterodimeric interferon receptor complex (IFNAR1/IFNAR2) in an autocrine or paracrine manner.
This initiates a series of intracellular phosphorylation events, involving the adaptor proteins signal
transducer and activator of transcription (Stat)2, tyrosine kinase 2 (Tyk2) and Janus kinase 1 (Jak1)
(Fig.1). Phosphorylation of these adaptors provides a docking site for Stat proteins that are then
activated via the kinase activity of the IFNAR1 complex (62,63). Phosphorylated Stats form hetero-
and homodimeric transcriptional activator complexes that translocate to the nucleus, drive expression
of IFNα and interferon stimulated genes (ISGs) and modulate the expression of hundreds of other
genes (62). The type I IFN response is turned off by the activity of suppressor of cytokine signalling
(SOCS3) protein family members, for example SOCS3 associates with the IFNR, inhibits Jak activity
and promotes Jak proteosomal degradation (64–66).
ISG expression establishes a cellular antiviral state that both enables a cell to restrict intracellular virus
replication and protects bystander cells from viral infection (67). As such, the type I IFN response is
the main weapon of the innate immune system against viral infection, as highlighted by the extensive
array of strategies viruses use to evade detection by PRRs, induction of type I IFN and type I IFN
inducible signalling events (68). A ‘non-classical’ pathway for activation of ISGs by type I IFN also exists,
involving the intracellular signalling mitogen-activated protein kinase (MAPK) and phosphoinositide 3-
kinase (PI3K) pathways and regulation at the level of ISG messenger RNA (mRNA) translation (60,62,69).
1.7 ISGs
The activities of a number of ISGs have been well characterised. Many, such as protein kinase R (PKR),
have generalised antiviral effects (70,71). These include the cytosolic enzymes activated by dsRNA, such
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as PKR and 2-5-oligoadenylate (2-5(A))-synthetases (OAS) (70–73), the myxovirus resistance protein
(Mx) and Guanylate binding proteins that interfere with virus replication by inhibiting nuclear transport
of viral nucleocapsids (74), and ISG56 family members that inhibit host cell protein synthesis via inhibition
of eukaryotic initiation factor (eIF)-3 function (75).
dsRNA induces dimerization and autophosphorylation of PKR (76), leading to PKR mediated phospho-
rylation of the α subunit of the eIF-2 complex (77). This results in general translation shut-off, induction
of cell death (78) and inhibition of virus replication (76). PKR activation is highly regulated, for exam-
ple by cellular TAR RNA binding protein (TRBP), adenosine deaminase acting on RNA (ADAR1) and
PKR activator (PACT). During HIV-1 infection PACT inhibits PKR activation (79), whereas HSV-1 Us11
protein inhibits PACT mediated PKR activation (80).
OASs are nucleotidyltransferases that produce 2’-5’-oligoadenylates. These bind and activate RNase
L, which then mediates degradation of viral and cellular RNA (81,82). Interestingly cGAS, the recently
discovered DNA sensor, is an OAS homologue. The functional similarity of cGAS and the OAS system
has recently been reviewed (83). Full activation of OASs in virally infected cells leads to the inhibition
of protein synthesis and induces apoptosis (84). HSV-1 Us11 also inhibits OAS activation, late during
viral replication (85).
Mx proteins are dynamin-like large GTPases, best known for inhibiting the replication of negative-
stranded RNA viruses, such as influenza (74). However, they also have activity against other virus types.
The antiviral role of Mx proteins appears linked to their ability to detect nucleocapsid structures in the
cytoplasm (86).
Other ISGs have effects limited to certain virus types, for example retrovirus restriction factors such as
apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like (APOBEC)3G/3F, tripartate motif
protein (TRIM5)-α and tetherin (87–90), although these can also have activity against other viruses
including HSV-1 (91–94).
The APOBEC family of cytidine deaminases catalyze the deamination of cytidine to uridine in single-
stranded nucleic acids. They interfere with retroviral replication via hypermutation of the viral
genome, inhibition of reverse transcription, and inhibition of provirus integration into the host genome.
APOBEC3DE, APOBEC3F, APOBEC3G, and APOBEC3H all have anti-retroviral activity (95). HIV-1
Vif counteracts the activity of the APOBEC restriction factors by a variety of mechanisms, includ-
ing inducing the formation of a E3 ubiquitin ligase complex to direct degradation of APOBEC pro-
teins (96–101), depleting the intracellular pool of ABOBEC3G by directly binding ABOBEC3G mRNA
and down-regulating its translation and stability (98,102,103) and directly inhibiting ABOBEC3G deamina-
tion activity by altering its processive DNA scanning mechanism (104). APOBEC proteins do have activ-
ity against herpesviruses, including HSV-1, but it is not yet known whether HSV-1 encodes APOBEC
antagonists (94).
Tetherin prevents the release of virus particles after they have budded from infected cells. HIV-1 is
able to counteract the activity of tetherin (105–107). Recently, tetherin was also shown to have activity
against HSV-1 (91,92) and HSV-1 gM is able to counteract this effect.
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Many more ISGs have yet undefined functions or functions that do not appear related to antiviral
immunity (108). Modulation of these genes may reflect the immuno-regulatory role of type I IFN (109).
Type I IFNs can have global effects on the innate immune system (110), for example, they can promote
NK cell-mediated and CD8+ T cell mediated cytotoxicity (111), trigger apoptosis of virally infected
cells (112) and enhance maturation, cross-presentation, antigen presentation and migration of dendritic
cells (DCs), thereby promoting activation of the adaptive immune responses (113,114). Type I IFN can
also enhance Th1 cell responses and promote the generation of T follicular helper (Tfh) cells (115–117).
1.8 Cell death
Ligation of PRRs can lead to activation of programmed cell death pathways (118). Death of an infected
cell can have advantageous consequences for the host, such as eliminating cellular reservoirs of viral
infection (119–121), preventing high-jacking of cellular machinery for the purposes of viral gene expression,
genome replication and protein expression (122,123), and alerting the immune system to danger (124,125).
Many viruses encode or activate cell survival factors in order to counteract the cell death response early
during viral infection (126–129). However, cell death can also be advantageous for a virus, for example,
by facilitating virion release and eliminating cells alerted to infection (130). Consequently, the interaction
between cell death responses and viral replication can be complex (131).
Cell death can occur by apoptosis, pyroptosis, necroptosis or necrosis (132–135). These cell death path-
ways can be distinguished on the basis of the activation signal, the nuclear morphology and plasma
membrane integrity of the dying cells, the activity of specific cell death inhibitors and the cell-types
in which they occur (136,137). Necrosis is an unprogrammed form of cell death characterised by cellular
swelling, membrane blebbing, complete breakdown of the plasma membrane and release of cytoplas-
mic contents into the extracellular fluid (137). Pyroptosis is defined as caspase-1 dependent cell lysis (138)
and was first described in Salmonella typhimurim and Shigella infected macrophages (139,140). Pyropto-
sis is activated via the formation of inflammasome complexes and is often accompanied by interleukin
(IL)-1β and IL-18 release (141) (Fig.2). Apoptosis is defined as the caspase-dependent breakdown of
the cell components into apoptotic bodies (142). Apoptotic cells undergo morphological changes char-
acteristic of only this form of cell death, these include membrane blebbing, cell shrinkage, nuclear
fragmentation, chromatin condensation and chromosomal DNA fragmentation. Apoptosis can be acti-
vated by the extrinsic pathway, via death receptors on the cell surface, or the intrinsic pathway (143) via
mitochondrial dysfunction and cytochrome c (cyt c) release (144). Death receptors include the TNF-α
receptor and Fas receptor. Finally, necroptosis is a cell death pathway involving RIP3 and/or RIP1 sig-
nalling (128,145), in the absence of caspase-8 activation (Fig.3) (146–148). It has a role in development
and immune responses (128,145,148,149), and is often activated following inhibition of apoptosis, pyropto-
sis or both (146–148). The morphological characteristics, activating signals and receptors and cell-types in
which each cell-death pathway can occur are summarized in Table 3. There can also be considerable in-
teraction between the cell death pathways, for example LPS activation of macrophages redirects Yersina
induced macrophage cell death to caspase-1 dependent pyroptosis from caspase 8/3, cyt c dependent
apoptosis (150).
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Herpesviruses are among the largest and most complex of human viruses (151). Herpes virions are rela-
tively large, 100-200nm in diameter, enveloped and contain a double-stranded DNA viral genome within
a icosahedral capsid formed of viral protein (152,153). Herpesvirus genomes include 70-200 predicted open
reading frames (ORFs) (154), providing the genetic diversity and complexity that enables herpesviruses
to both manipulate the host cell environment and the immune system (155). Herpesviruses have a highly
co-ordinated pattern of gene expression that involves both temporally regulated recruitment of cellular
transcription complexes and epigenetic manipulation (156–158).
A characteristic of all herpesviruses is their capacity to establish a long-term latent infection in their
host (159). In some host cells a static state of viral latency is established involving the repression of lytic
gene expression, the expression of latency associated viral factors and persistence but not replication
of the viral genome (160–162). In other cells, lytic viral gene expression occurs, leading to genome
replication, the production of nascent virions, virion release and cell death. As described in detail
below with respect to HSV-1, the tropism of herpesviruses, as well as their capacity to establish a
latent infection, is determined by the cell receptors expressed and intracellular conditions of the host
cell (151). These intracellular conditions can include the differentiation state of the cell, whether the cell
is activated against viral infection by, for example, type I IFN stimulation, and whether the cell is in a
pro or anti-apoptotic state (151).
1.10 HSV-1
HSV-1 belongs to the α-herpesviridae sub family, of which varicella zoster virus (VZV) and HSV-2
are also members. Viruses in this family typically have narrow species tropism and broad cell tropism.
They generally target neurons for long term residence, but also replicate in epithelial cells - a stage
necessary for efficient virion transmission from the skin or mucosa. HSV-1 is typically associated with
cold sores, or blisters, on the lips. HSV-2 is associated with genital blisters. However, both viruses can
cause lesions at either site, and HSV-1 is becoming the leading cause of genital herpes in the developed
world (163).
Following transmission to the mucosal epithelium, an HSV-1 lesion appears a few days after infection.
At the lesion, infected epithelial cells release virions and die. HSV-1 virions then enter sensory neurons
innervating the site of transmission, are transported up the nerve axon to the nucleus and establish a
life-long latent infection in the neuron. Latent HSV-1 re-activates throughout life, as a result of external
stimuli such as stress, cold and immune-system repression. Re-activation can result in assymptomatic
virus shedding or HSV-1 lesions. The HSV-1 replication cycle is represented schematically in Figure 4.
HSV-1 has a global prevalence of 70-90%, as determined by seropositivity (163). 50% of individuals who
experience symptomatic HSV-1 primary infection will have recurrent HSV-1 disease (164), although the
symptoms of primary infection are generally more severe than recurrent infection. Cold sores are the
most common type of HSV-1 lesions. However, HSV-1 can also cause diseases associated with the skin,
eyes and brain.
HSV-1 cutaneous lesions occur around the skin of the nails and this used to be a common problem for
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dentists working without gloves (165). HSV-1 infection of the eye can cause keratitis and blindness (166),
and HSV-1 lytic replication in the brain can lead to encephalitis and meningitis (167). Herpes simplex
encephalitis (HSE) causes significant mortality and neurological morbidity (168). HSV primary genital
infection is associated with foetal loss, premature labour and neonatal HSV infection (169). Neonatal
HSV infection is rare but has high morbidity and mortality. Symptoms range from isolated skin, eye and
mucous membrane disease, to central nervous system (CNS) disease (170–172). Severe HSV-1 primary
disease and recurrent infections are also a significant risk for immuno-compromised patients. Compli-
cations of HSV-1 infection in acquired immunodeficiency syndrome (AIDS) and transplant patients can
include pneumonitis and hepatitis (4,173–175).
The majority of HSV-1 disease can be treated with acyclovir (ACV). ACV is a guanosine analog that acts
as an antimetabolite, inhibiting HSV-1 genome replication. Prophylactic ACV treatment can also be
used to reduce the risk of recurrent HSV-1 lesions and infection in solid organ and haemotatic stem cell
transplant patients. However, the overall management of HSV disease is complex, due to the variability
of the host-pathogen interactions involved (171), for example it is often unclear whether the immune
response to HSV-1 infection is beneficial or harmful to the host, and the ability of HSV-1 to establish
a latent infection means that it is currently impossible to eradicate it from the host. An over-active
immune response to HSV-1 infection underlies the pathogenesis of HSV-1 encephalitis, whereas HSV-1
reactivation from latency is often associated with immune-suppression. It is generally accepted that
there is a need for a greater understanding of HSV-1 pathogenesis to aid future research into targeted
drug therapies and vaccine development (176).
The molecular virology of the HSV-1 lytic and latent replication cycles have been well characterized
in tissue cultured epithelial cells, animal models and cultured neurons. In epithelial cells HSV-1 lytic
replication occurs by tightly regulated sequential expression of viral immediate early (IE, α), early (E,
β) and Late (L, γ) genes. Following virion entry into an epithelial cell, the virion protein VP16 is
transported to the nucleus along with the viral genome. VP16 activates expression of the IE gene
infected cell polypeptide (ICP)0 by unravelling the HSV-1 episomal genome from the heterochromatin
state that host cell factors would otherwise establish. ICP0 activates expression of the other IE proteins
within 2-4 hours of infection, by sequestering the transcriptional repression complex REST corepressor
1 (co-REST)/RE1-silencing transcription factor (REST)/host cell factor 1 (HCF-1). IE proteins induce
expression of the E genes within 4-8 hours post infection. These genes include viral DNA polymerase
(DNA Pol) and virus thymidine kinase (TK), and have roles in viral DNA replication and promoting
cell survival, activating L gene expression and suppressing IE gene expression. L viral genes are divided
into two types, leaky late (γ1) and true late (γ2) genes. Leaky late genes include glycoprotein B (gB),
ICP34.5, gD and ICP5 and are expressed independently of viral genome replication (177). True late genes
are expressed 8-12 hours post infection and form the structural components of nascent virions, activate
virus release and promote cell death (178). The processes of HSV-1 gene expression are represented
schematically in Figure 5.
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The major site of HSV-1 latency is the ganglionic sensory neurons, primarily the trigeminal ganglia
(TG) and the sacral dorsal root ganglia (179–181). However, latent HSV-1 has also been detected in the
human adult nodose ganglia and vagus nerve (182,183).
There are three steps involved in the establishment of HSV-1 latency (184). First, acute infection at the
mucosal epithelium leads to the production of a high amount of infectious virus. This is followed by
entry of virions into sensory neurons. Viral gene expression is then extinguished, with the exception
of the HSV-1 latency associated transcript (LAT), as productively infected cells die. HSV-1 latency
is thought to occur when activation of ICP0 expression by VP16 and ICP0 dependent activation of
IE gene expression is stalled (185). During productive infection VP16 induces IE gene expression by
recruiting cellular transcription factors, including HCF-1, Oct1, lysine specific demethylase-1 (LSD1),
and CLOCK histone acetyl transferase, such that the IE promoter is demethylated and transcription
activated (185,186). In neurons, VP16 and the cellular HCF-1, are not translocated to the nucleus. IE
transcription is therefore not activated and the viral genome is suppressed. The blocks to HSV-1
replication that can lead to latent infection are represented schematically in Figure 6.
During latency, the HSV-1 LAT accumulates, promoting cell survival and dampening down IE and E
expression. Latent HSV-1 can be re-activated from the neurons by external stimuli, such as stress or
immuno-suppression. During reactivation, infectious HSV-1 virions can be isolated from the TG and/or
eye and nose swabs. It is not known whether latently infected neurons in which productive HSV-1
infection re-activates, survive and re-establish latency, or are killed.
Experimentally, there are two recognised forms of HSV-1 latency: ”canonical latency”, defined as the
presence of episomal, circularized viral DNA in the absence of viral protein expression, DNA replication
and virion production; and ‘non-canonical latency’ or quiescent infection, where HSV-1 replication is
blocked at some point after IE gene expression, but prior to late gene expression and virion production.
In any assessment of HSV-1 infection, it is important to determine how HSV-1 replication proceeds,
and to distinguish between lytic replication, canonical latency and quiescent infection. This requires
assessments of HSV-1 infection at the level of IE, E and L gene and protein expression, virion production
and cell death.
The molecular mechanisms of HSV-1 latency in vivo remain poorly understood. This is partly due to
the difficulty of assessing what is essentially the lack of replicative infection in vivo and the inadequacy
of in vitro models. It is impossible to subject cells in tissue culture to the same stresses that a body
can receive. Additionally, an infection aborted due to the lack of ICP0 expression by a ICP0− virus,
for example, may not be a realistic representation of latent HSV-1 infection of neurons. Consequently,
there is considerable opportunity for improving our knowledge of HSV-1 latent infection.
1.12 HSV-1 in vitro
Multiple HSV-1 strains have been isolated and studied, including strain 17, KOS, strain F and SC16.
HSV-1 is less susceptible to genetic mutation than other herpesviruses (187). However, there are still
significant genetic differences between many HSV-1 laboratory and wild-type strains. These are of-
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ten in genes encoding proteins that are essential for in vivo pathogenesis, but not for growth in tissue
cell lines, for example the HSV-1 thymine kinase gene (188). Additionally, during HSV-1 genome repli-
cation, homologous recombination can occur (154,189). Consequently, laboratory strains of HSV-1 that
have undergone multiple passaging, may give misleading data regarding the host pathogen interactions
between HSV-1 and non-tissue culture cells, such as monocyte derived macrophages. Highly passaged
HSV-1, for example, may have lost the capacity to interfere with type I IFN responses.
1.13 PRR detection of HSV-1
Multiple HSV-1 PAMPs and HSV-1 specific cellular PRRs have been identified. HSV-1 PAMPs include
virion surface glycoproteins, the C-G rich viral genome, tegument protein and viral RNA (190). The
signaling pathway activated in response to HSV-1 infection will be highly dependent on the PRR(s)
activated. Detection of HSV-1 can lead to type I IFN signaling, release of inflammatory cytokines, and
NF-κB, p38 and AP-1 signaling. PRRs that detect HSV-1 PAMPs are summarized in Table 4. As with
PRRs in general, it seems odd that so many cellular proteins are needed to detect HSV-1 infection. It
is possible that there is some redundancy in the system. Alternatively, it may be that these receptors
function in a cell specific manner. One group has shown, for example, that HSV-1 can be detected by
Mda5 but not by Pol III in macrophages (191). Consequently, yet again there is considerable opportunity
to investigate HSV-1 detection in a clinically and immunologically relevant cell model.
1.14 HSV-1 and type I IFN
Detection of HSV-1 PAMPs by cellular PRRs leads to induction of a type I IFN response (192–195).
Type I IFN has well-established anti-viral effects against HSV-1, but HSV-1 is also able to counteract
these effects in a context dependent manner. IFN-β is highly expressed in the TG of HSV-1 infected
mice (192,196) and has been proposed to play an important role in HSV-1 disease (196).
Type I IFN has an antiviral effect against HSV- 1 in both tissue culture (197,198) and the TG (196). In
mouse models of HSV-1 infection, type I IFN increases cell survival and decreases virion production (196).
In both HeLa cells and mouse macrophages, type I IFN can block HSV-1 infection prior to IE gene
expression (199–201). In a mouse model lacking the IFNR, footpad or ocular inoculation where normally
the infection would be controlled leads to systemic dissemination of the virus (202). Administration of
interferon promotes survival of HSV-1 infected mice (195,203–205). Finally, a partial reduced ability to
produce type I IFN in response to TLR3 stimulation, resulting from TLR3 deficiency, can lead to herpes
simplex encephalitis (HSE) whilst the patient remains resistant to other infections (206,207). However,
type I IFN also plays a role in immuno-pathogenesis during HSV-1 infection and type I IFN blocking
antibodies or the genetic lack of the IFNR reduces the severity of HSV-1 disease in mice (208).
HSV gene products can counteract the host interferon response, for example by decreasing transcription
of the ISG PKR and reducing Jak-1 and Stat-1 phosphorylation (196,209), or preventing the nuclear
accumulation of IRF3 prior to infb transcription (210,211). HSV-1 also increases transcription of the
negative regulator of type I IFN responses, SOCS3, in cell cultures treated with IFN-β (196,212,213).
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1.15 HSV-1 and cell death
HSV-1 can both cause and inhibit cell death. In vitro HSV-1 is a highly lytic virus and can be
used in vivo as a cytolytic tool during cancer therapy (214–219). Conversely, like all DNA viruses, HSV-1
possesses multiple strategies to maintain host cell survival throughout viral replication (220) and inhibition
of cell death by HSV-1 is believed to be important for the establishment and maintenance of viral
latency (221,222).
The separation of HSV-1 research into the investigation of either pro-death or anti-death signalling, by
cancer researchers and molecular virologists respectively, has lead to confusion and conflicting results
within the literature. However, the fundamental question of whether HSV-1 is pro-death or anti-death
may be misleading. There is growing appreciation that a balance between pro-survival and pro-death
signalling is established within an HSV-1 infected cell, and that this is dependent upon the cell type
and the stage of the viral replication cycle.
HSV-1 infection of many tissue culture cells, and some primary cells, causes cytotoxicity (218,219). HSV-
1 induced cell death often has characteristics of necrosis and may merely reflect cell lysis resulting
from the high viral load within HSV-1 infected cells. However, there is growing evidence that HSV-1
dependent cell lysis is at least partly dependent on cell death signalling pathways, and is not a result
of un-programmed necrosis (223). Indeed, HSV-1 has been shown to induce both caspase dependent
and independent apoptosis and HSV-1 factors that promote apoptosis have been identified. Although
conversely, in the majority of cases, these proteins also have anti-apoptotic effects.
Additionally, there is a growing realization that what would once have been considered uncontrolled
cell death, actually results from carefully orchestrated cell signalling events, for example in the cases
of pyroptosis and necroptosis (223). As described above, from a morphological perspective, these forms
of cell death are indistinguishable from necrosis (138). It seems likely that the cytolytic ability of HSV-1
involves one or more of these pathways, potentially in combination with apoptosis (224). The evidence
for this is summarized in Table 5.
A number of HSV-1 genes and cell signalling pathways have been linked with HSV-1 dependent anti-
apoptotic and pro-survival signalling, these are summarised in Table 6. Of particular interest is the anti-
apoptotic ability of HSV-1 LAT, and the linking of this function with the ability of LAT to re-activate
latent HSV-1. Interestingly, many anti-apoptotic proteins can substitute for the LAT as promoters
of reactivation (225–228) and pro-apoptotic drugs such as 2[3-(2,3-dichloro-amino]-ethanol (DCPE) and
Dexamethasone, can accelerate viral lytic gene expression (221). This was demonstrated in an infection
model where latency and reactivation occur within the context of a single replication cycle (221).
It seems probable that during HSV-1 infection multiple cell death pathways, including apoptosis, py-
roptosis, and necroptosis, will be both activated and inhibited. The net result of these effects will be
dependent upon the stage of the viral replication cycle, the cell type and whether a productive or la-
tent viral infection is established. There are also likely to be autocrine and paracrine effects involved
that result as an effect of the HSV-1 induced secretosome, for example those potentially mediated by
type I IFN. Considerable opportunities remain to investigate the interaction of HSV-1 with cell death
signalling in a clinically relevant cell type such as macrophages.
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1.16 HSV-1 infection of macrophages
HSV-1 is an ideal virus with which to study macrophage antiviral strategies. HSV-1 has already been
widely used to identify and study PRRs, as described above. Additionally, as an α-herpesvirus, HSV-1
has broad cell tropism (151,229) and has previously been shown to infect human macrophages (197,230–235).
Finally, considerable data demonstrate the importance of macrophages during HSV-1 disease, par-
ticularly in mouse models of infection, for example in the control of HSV-1 replication at HSV-1
lesions (11–13,236,237). In the absence of macrophages, HSV-1 disease in mouse models of encephali-
tis, retinitis (11) and keratitis (12) for example, is more severe. In the model of keratitis, in particu-
lar, immunopathological corneal destruction following HSV-1 infection is profoundly accelerated by
macrophages in the lymph nodes (12).
HSV-1 can infect macrophages in vitro. Freshly isolated human monocytes cultured ex vivo for a
period of at least 3 days become susceptible to productive HSV infection (197,230–235). HSV-1 viral
mRNA is expressed (233,235), viral DNA replicated (232), and nascent virions produced (197,232). 80% of a
macrophage culture can be infected (231).
Primary monocytes possess a block to HSV replication that is removed upon differentiation into
macrophages, for example, differentiation of U937 cells with phorbol 12-myristate 13- acetate (PMA),
vitamin D3 or mezerein (a phorbol ester analogue) induces a susceptibility to productive HSV-1 infec-
tion (238–241). The mechanism by which this occurs in unknown, although it is known that it is not due
to the reduction of nitric oxide upon differentiation (241), and may be due to the dysfunction of ICP0 in
undifferentiated cells (240).
Infection of freshly isolated human monocytes with a high MOI of HSV stimulates IFNα produc-
tion (242–244), even in the absence of viral DNA synthesis (243). HSV-1 infection of macrophages induces
type I IFN production, ISG expression and inflammatory cytokine production, including expression of
TNFα, CXCL10 (IP-10), CCL2 and CCL3 (191). The type I IFN response is dependent upon Mda5,
whereas the production of TNFα, CXCL10, CCL2 and CCL3 is Mda5 independent. Type I IFN has
been shown to both inhibit and have no effect on HSV-1 infection (197,232). HSV-1 dependent type I
IFN production is also virus strain dependent (197,233,243,245). In these experimental models, the multi-
ple HSV-1 encoded proteins that have been shown to counteract IFN signalling and induction in other
contexts, appear to be ineffective during macrophage infection.
HSV-1 can cause cytopathology of primary human monocytes (230,234), U937s (238,246), THP-
1s (234,247,248) and mouse peritoneal macrophages (249). HSV-1 dependent death of human monocyte
derived macrophages has not been detected (234,235).
In humans, inflammatory macrophages can be detected at HSV reactivation lesions at least 2 days
from the first detection of the lesions (250,251) and are thought to play an important role in the early
defence against HSV-1 infection (11–13,236,237,252). However, more research is needed regarding the role
of macrophages in human HSV-1 infection, for example whether they play a protective role or contribute
to the immunopathology that is the hallmark of serious HSV-1-mediated disease. However, given the
well documented ability of HSV-1 to infect macrophages in vitro and the central role of macrophages
to innate immune responses, it is likely that macrophages play an important role in HSV-1 disease
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especially in the context of HIV-1 co-infection.
1.17 HIV-1
HIV-1, the causative agent of AIDS, was first identified in the the US in 1983 (253). Since then, the
World Health Organisation (WHO) estimates that over 60 million people have been infected with HIV-1
and that it has been responsible for over 25 million deaths.
HIV-1 belongs to the lentivirus family of retroviruses. Retrovirus virions are enveloped and contain a
protein capsid enclosing two copies of the relatively small ssRNA virus genome and a number of viral
proteins. One of these proteins is the reverse transcriptase (RT) responsible for reverse-transcribing the
RNA genomes into a double-stranded provirus, following virion entry and release of the viral genome
from the capsid. The provirus translocates to the nucleus where viral integrase and protease inserts it
into the host cell genome, form where it is transcribed. HIV-1 protease also cleaves newly synthesized
HIV-1 polyproteins to produce the polypeptides that are assembled into the HIV-1 virion. The HIV-1
replication cycle is represented in Figure (254).
A number of HIV-1 accessory proteins, including Tat and Nef, function to enable LTR transcription
and viral gene expression (Table 7). Additionally, the HIV-1 LTR promoter contains specific binding
sequences for cellular transcription factors that function to initiate and/or enhance HIV-1 transcription,
as reviewed in (255) and summarized in Table 8 (although this list is by no means exhaustive). Given
the involvement of cellular factors in the promotion of HIV-1 transcription, it comes as no surprise
that co-infecting pathogens, including HSV-1, and cell stimulants can indirectly activate or enhance
HIV-1 transcription, and a number of examples of this are described in Table 12. Again, this list is not
exhaustive and indeed, it is difficult to find an intracellular pathogen that can not increase HIV-1 LTR
transcription in some setting. It will be interesting to determine whether HSV-1 interacts with HIV-1
transcription in clinically relevant host cells, such as macrophages. Interestingly, histone deacetylase
inhibitors can both enhance HIV-1 transcription and reactivate latent HSV-1 (256–259).
1.18 HIV-1 infection of macrophages
Macrophages are major cellular targets of HIV-1 in vivo and are thought to contribute to the patho-
genesis of disease (9,10). HIV-1 is able to infect macrophages without evident cytopathology, syncytia
formation or activation of type I IFN responses in vitro (9). This may explain the ability of HIV-1 to es-
tablish long-term virus reservoirs in macrophages where it can effectively hide from the adaptive immune
responses that deplete HIV-1 infected lymphocytes, although this remains controversial (8).
HIV-1 infection of macrophages and other myeloid cells is sensitive to type I IFN treatment (87,260–262),
so the ability of HIV-1 to avoid the innate immune detection mechanisms of these cells may be an
important survival strategy for the virus (9,10,87,262). Therefore, understanding the interaction between
HIV-1 and macrophages during HIV-1 infection is the subject of active research for those interested in
the eradication of HIV-1 and HIV-1 vaccine development (8).
There is controversy over whether HIV-1 directly induces cell death in macrophages (263). There is an
extensive body of literature indicating that HIV-1 does not cause cytopathology in macrophages (264).
There is also evidence that HIV-1 infection may even protect HIV-1 from apoptosis (265,266). However
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there have also been reports of HIV-1 induction of apoptosis in macrophages (267,268) and there is
evidence that HIV-1 infected macrophages can induce apoptosis of bystander cells (269,270). It will be
interesting to see whether any apoptosis or cytopathology observed in herpesvirus infected macrophages
is affected by HIV-1 coinfection.
Given the importance of macrophages in HIV-1 infection, it is of interest how co-infecting pathogens
will affect the response of macrophages to HIV-1. This may also illuminate aspects of HIV-1 virology,
for example, whether HIV-1 infection can protect macrophages from the cell death and type I IFN
responses that would otherwise be induced by infection with another virus. Alternatively, whether
the type I IFN response induced in response to another virus can protect macrophages from HIV-1
infection.These questions are of particular relevance for opportunistic pathogens that cause disease
during AIDS, pathogens that can infect macrophages, pathogens that increase transmission of HIV and
pathogens that significantly interact with innate immune responses. HSV-1 satisfies these criteria.
1.19 HIV-1 and type I IFN
Type I IFNs can stimulate expression of antiretroviral genes and restriction factors that inhibit HIV-1
replication and spread in vitro. IFNα and β levels in the blood increase significantly following viral
dissemination. Despite this, HIV-1 is able to replicate and establish persistent viremia in sero-converted
infected patients (113).
Macrophages, monocytes, CD4+ and CD8+ T cells, NK cells and B cells all show evidence of long
term stimulation by type I IFNs in HIV-1 infected patients (271–274). Specifically, CD4+ and CD8+ cells
from HIV-1 infected individuals have a characteristic pattern of gene expression that suggests chronic
stimulation by type I IFNs. Furthermore ISG are induced in the B cells of viremic but not aviremic
patients or healthy controls (272). Finally, ISGs are down-regulated in post-HAART lymph-node biopsy
samples compared to pre-treatment samples (273).
HIV-1 is able to counteract the antiviral effects of type I IFN observed in vitro during pathogenic
infection. In fact, it remains to be determined whether the rapid and transient peak of IFNα production
in primary HIV-1 infection has a positive or detrimental role in regard to set point determination
and progression to AIDS, an effect that is probably also strongly determined by the cells and ISGs
that mediate the type I IFN responses. In pathogenic SIV infection of its non-natural host there
is a delay between initial infection and IFN production at the transmission site, compared to non-
pathogenic infection of the natural host (114). Blocking the IFNR in this model decreases antiviral gene
expression, increases the reservoir of target cells and accelerates CD4+ T cell depletion, whereas IFN-
α2a administration up-regulates expression of antiviral genes and prevents systemic infection (275). It has
also been proposed that one way in which long-term nonprogressors (LTNPs) successfully control HIV-1
infection is by a type I IFN dependent containment of HIV-1 at the transmission sites (116), allowing
enough time for the adaptive immune system to mount an efficient response to the virus prior to virus
dissemination. However, long term stimulation by type I IFN has been proposed as a mechanism for
the aberrations of immune cell function characteristic of chronic HIV-1 disease. In the pathogenic SIV
infection model, continued IFN-α2a treatment induces type I IFN desensitization and decreases antiviral
gene expression. This leads to an increased SIV infection reservoir size and accelerates CD4+ T-cell
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loss. It is therefore clear that type I IFNs play some role in AIDS but it remains to be determined if
they are beneficial or detrimental to the host.
Production of type I IFN by HIV-1 infected cells can promote apoptosis of uninfected bystander CD4+ T
cells and up-regulate cell-cycle control associated ISGs, leading to the lymphopenia that is the hallmark
of AIDS (276,277) . IFNβ, the main type I IFN produced during initial immune responses to the presence
of HIV-1 in the central nervous system (CNS), is thought to be linked to progression to AIDS associated
dementia (278). On the other hand a recent study by Tavel et al showed that treatment of asymptomatic
HIV-1 positive patients with IFNα-2b can significantly decrease HIV-1 RNA levels in the blood, without
reducing the percentage of CD4+ cells present (279) .
1.20 SAMHD1 and vpx
In this study I use a single-round model of HIV-1 infection where envelope (env) deleted HIV-1
(∆envHIV-1) is VSV-pseudo-typed and delivered to macrophages in trans with VSV-SIV expressing
vpx. Vpx is an HIV-2 and SIV accessory protein packaged into viral particles via an interaction with
Gag (280–282). It is necessary for the efficient replication of HIV-2 and SIV in myeloid cells (283–287). Vpx
also enhances HIV-1 infection of macrophages (288), enabling the study of macrophage responses to
single-round HIV-1 infection.
Single-round infection models and lentivector systems have demonstrated that vpx plays a role in the
nuclear import of pre-integration complexes in non dividing cells such as macrophages (289,290). Upon
virion entry, vpx localises to the nucleus of infected cells (290–292). It is controversial as to whether vpx
then shuttles between the cytoplasm and nucleus, and whether this underlies the function of vpx in
nuclear import (292).
Vpx increases the efficiency of HIV-1 infection of macrophages by degrading the cellular restriction fac-
tor SAMHD1 (293,294). SAMHD1 has broad activity against a range of retroviruses (295,296) as well as
DNA viruses such as VZV and HSV-1 (297,298). It is a deoxynucleoside-triphosphate (dNTP) phospho-
hydrolase (299–301) that decreases the pool of dNTPs available for reverse transcription in myeloid cells
and non-cycling T cells (302–304). The enzymatic and restriction activity of SAMHD1 is inhibited by
CDK1 mediated phosphorylation (305,306). CDK1 is inactive in resting cells, and given that SAMHD1
levels are equivalent in active T cells and macrophages (304), this, along with the higher dNTP concen-
tration in cycling T cells than macrophages (307), may explain the inability of SAMHD1 to restrict HIV-1
replication in cycling T cells. SAMHD1 may also mediate a dNTP independent restriction effect, for
example it can interact with and degrade specific nucleic acids, including ssRNA and ssDNA (308,309).
Vpx recruits the DCAF1-DDB1-CUL4A E3 ligase complex (310–313), in order to facilitate degradation of
SAMHD1. The interaction between SAMHD1, vpx and HIV-1 are represented schematically in Figure
8.
The susceptibility of HIV-1 infection of macrophages to type I IFN mediated restriction (87,260–262)
has been partly attributed to the activity of SAMHD1, not least because the IFN induced block is
primarily exerted at the level of DNA accumulation (87,261,262), and vpx increases HIV-1 replication in
IFN-treated myeloid cells (314–316). Although not an interferon inducible gene (316), SAMHD1 is de-
phosphorylated, and thereby enzymatically activated, by type I IFN stimulation (305). Furthermore, IFN
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mediated restriction of HIV-1 replication can be reduced, if not abolished, by delivery of vpx or silencing
of SAMHD1 (316). Recently, HSV-1 has been shown to counter-act SAMHD1 activity (298). It will be
interesting to see whether vpx interacts with HSV-1 infection of macrophages.
Vpx also sequesters and decreases the stability of APOBEC3A (317,318), an ISG and potent restriction
factor of HIV-1 replication in myeloid cells (319–321).
1.21 HSV-1 and HIV-1 co-infection
HSV-1 and HIV-1 interact at an epidemiological, clinical and molecular level. An estimated two thirds
of the individuals infected with HIV-1 worldwide are also co-infected with HSV-1/2 (322,323). HIV-1
and HSV have similar routes of infection, can infect the same target cells, interact significantly with
the immune system and have high prevalences within the same regions of Sub-Saharan Africa (176).
At the population level, HSV infection is correlated with increased HIV-1 transmission and disease
severity (14,15,104,324–338) and vice versa (176,323,339–342). Additionally, HIV-1 infection allows re-activation
of latent HSV-1 via suppression (343) and promotes HSV-1 dependent life-threatening disease during
AIDS (14).
HSV infection increases HIV-1 transmission within a population (14,15,104,325,330–333). In a meta-analysis
Freeman et al demonstrated that HSV-2 sero-positivity was a statistically significant risk factor for HIV-
1 acquisition in general populations of men (summary adjusted risk ratio [RR] 2.7; 95% Confidence
Interval [CI] 1.9-3.9) and women (RR, 3.1; 95% CI 1.7-5.6). Furthermore, a recent mathematical model
describing the transmission dynamics of HIV-1 and HSV, demonstrated that HSV infection may not
only increase the risk of HIV-1 transmission but also may increase the peak of HIV prevalence, as well
as decreasing the time to that peak (344).
The increased susceptibility of HSV infected individuals to HIV-1 infection, and/or the increased infec-
tivity of HSV/HIV-1 co-infected individuals, may account for the population level interactions between
HSV infection and HIV-1 transmission (104,327,328,345–349). Both HSV-1 and HSV-2 cause genital ul-
ceration and mucosal disruption, and thereby provide a portal of entry to HIV-1 (329). Indeed, the
infectiousness of individuals positive for HIV-1 increases during periods of HSV reactivation (350), and
HSV genital reactivation, including asymptomatic shedding, increases the concentration of HIV-1 in
plasma and genital secretions (327,328,345,351). Furthermore, HIV-1 target cells, including CD4+ lympho-
cytes and macrophages, are recruited to herpetic lesions (104,335,352,353). In a study of the heterosexual
transmission between HIV-1 discordant couples in Uganda, genital ulcers resulting from HSV-2 infection
was associated with a four fold increase in HIV-1 transmission (325).
HIV-1 is correlated with increased HSV-1 infectivity (14). A number of mechanisms may be responsible
for this, for example, HIV-1/HSV-1 co-infection increases HSV shedding, HSV reactivation rates and
the duration of hepatic ulcers (176,340,350,354–357). Likely to be of particular importance is the immuno-
synergistic crosstalk between HIV-1 and HSV. HIV-1 co-infection impairs HSV specific CD4+ and
CD8+ T cell responses (356,357), and decreases Th1 cytokine and CCR5 ligand secretion in response
to HSV infection (343). Additionally, HIV-1 can facilitate HSV-1 entry by disrupting the oral mucosal
epithelial (358). The HIV-1 accessory proteins Tat and Gp120 disrupt epithelial tight junctions (359–361),
whilst HIV-1 infection also disrupts adhesion junctions by changing the localisation of the cell surface
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molecule, nectin-1 (358,362–364). Nectin-1 binds gD and is responsible for facilitating HSV-1 entry into
epithelial cells and HSV-1 cell-to-cell spread. Under normal circumstances, nectin-1 is sequestered in
intracellular junctions, limiting the access of HSV gD to this receptor (365). HIV-1 disrupts normal
nectin-1 localisation and increases its availability to HSV-1.
Untreated AIDS patients can demonstrate severe HSV-1 disease, as a result of being immunno-
compromised. Additionally, HIV-1 enhances the severity of HSV-1 associated disease (366).
Transfection of HSV-1 specific genes can activate HIV-1 transcription, for example the HSV-1 IE protein
ICP0 upregulates HIV-1 LTR transcription by recruiting NF-κB to the LTR promoter (335,367,368). HIV-1
and HSV coinfection of CD4+ cells (369–371) and DC (352,372) has been demonstrated. HIV-1/HSV-1
co-infection of macrophages has not been investigated, although HSV-2 has been shown to increase
the susceptibility of macrophages to HIV-1 infection by upregulating CCR5 expression levels on the cell
surface (373) and NF-κB activation by heat-inactivated HSV-1 virions can induce HIV-1 replication in
macrophages (374). However, another study has shown that HSV superinfection of PBMC from HIV-1
infected individuals, leads to greater HSV-1 virion production than infection of PBMC from healthy
donors, but that HSV-1 super-infection decreases HIV production (375). On the other hand, HSV has
been shown to increase expression of α4β7 and thereby facilitate amplification of HIV target cells. The
mechanism by which this occurs is unknown.
1.22 Summary
Considerable opportunity exists to explore the potential interactions between HSV-1, HIV-1 and
macrophages. Despite the clear potential relevance of macrophages to HSV-1 infection in vivo, cur-
rent knowledge is lacking in regard to the character of HSV-1 infection in these cells. There is also
considerable opportunity to explore the interactions of HSV-1 with macrophage cell death and type I
IFN responses. HIV-1 infection of macrophages is currently the subject of intense interest in the field.
Studying HIV-1 infection in the context of HSV-1 co-infection may provide novel insights into how both
these viruses interact with this important cell.
1.23 Objectives
In the following chapters, I will attempt to establish the following:
1. To confirm that HSV-1 can infect macrophages, and to investigate whether the infection is
productive and/or lytic and whether it induces a type I IFN response. I will also investigate
whether a latent HSV-1 infection of macrophages can be established.
2. To investigate the virological and cellular consequences of HIV-1 and HSV-1 co-infection of
macrophages.
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2 Methods
2.1 Macrophages
The macrophages used in this study were derived from adherent monocytes that were isolated from the
peripheral blood of volunteers, and differentiated into macrophages using recombinant M-CSF (GIBCO,
Cat. No. PHC2044) as previously described (9) (376). The study was approved by the joint University
College London/University College London Hospitals National Health Service Trust Human Research
Ethics Committee and written informed consent was obtained from all participants.
Adherent monocytes were differentiated into macrophages using RPMI 1640 (GIBCO Invitrogen) with
10% autologous heat-inactivated human serum (HS) and 20 ng/mL M-CSF (R& D systems) for 3 days
(Fig.9). The monocytes were allowed to adhere to the bottom of the wells of either plastic 24 cell
plates or CellCarrier-96 well black, optically clear bottom 96 well plates (product code 6005558). The
cells were incubated at 37◦Cin a 5% CO2 atmosphere.
On day three, non-adherent cells were removed by repeated washing. After washing, the medium was
replaced with RPMI 1640 containing 5% type AB human serum (Sigma-Aldrich). HSV-1 infections or
HIV-1 infections were performed 6 days after isolation of the cells from peripheral blood. This model of
monocyte derived macrophages has been extensively optimized and has been shown to have negligent
T cell contamination by day 6 of the protocol (377).
For each experiment, at least 3 replicates were performed with cells derived from different donors. The
approximate macrophage number per well could be estimated by determining the total number PBMC
isolated from every donor and assuming that adherent monocytes to comprise 5% of these cells.
2.2 Cell lines
Vero (African green monkey, immortalised fibroblast-like kidney cells), HeLa (Human, immortalised
cervical cancer cells) and HEK293T (Human, immortalised embryonic kidney cells) were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) media supplemented with 10% fetal calf serum (FCS).
They were grown as monolayers at 37◦Cin a 5% CO2 atmosphere or 10% CO2 atmosphere for the
HEK293T cells. All cells were passaged by trypsination and no more than 30 times.
2.3 HSV-1
Three strains of HSV-1 were used; SC16, +17-gB-GFP and +17-ICP0-YFP. These were kind gifts from
Dr Richard Milne (SC16) or Dr Melori Jones (+17-gB-GFP and +17-ICP0-YFP).
HSV-1 was propagated in Vero cells. The supernatants were harvested when≤90% cytopathic effect was
observed in vero cells in 175cm2 tissue culture flasks infected with HSV-1 at a MOI of 0.01pfu/cell. The
supernatants were centrifuged at 3000xg for 10 minutes, passed through a 0.45 filter and ultracentrifuged
through a 25% sorbitol cushion for 2 hours at 23,000rpm at 4◦Cusing a SW28 rotor. The resulting pellet
was resupended in RPMI 1640 (GIBCO Invitrogen) and stored at -80◦C. The virus was not passaged
more than 4 times.
Purified HSV-1 and the supernatents from HSV-1 infected macrophages were titrated by plaque assay
on vero cells, as has been previously described. Vero cell monolayers established in 24 well plates.
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HSV-1 virus was serially diluted in DMEM then each dilution used to infect a well of vero cells. After
24 hours, the media was removed, and replaced with DMEM-carboxymethylcellulose (2:1) media, and
the cells incubated as normal. 3 days post infection the media was removed, the cells fixed with ice cold
methanol and stained. The number of plaques were counted in the wells with a number of plaques in
the range of 5-20, and the concentration of infectious HSV-1 particles per ml of the original inoculum
calculated. A virus titre in the range of 1x108-109 was generally achieved.
2.4 Lentiviruses
Vesicular stomatitis virus (VSV)-G envelope pseudotyped replication deficient HIV-1 (R9 BaL ∆env),
full-length HIV-1 (R9 BaL) and VSV-pseudotype vpx were produced by transfecting HEK293T cells with
the appropriate plasmids (Table 9). The day before transfection, 6,5x105 HEK293T cells, passaged in
culture for at least 1 week, were seeded onto a 100mm tissue culture dish. 4 hours before transfection,
the media was refreshed. The cells were transfected using FuGENE 6 (Cat. No. E2691/2/3). For the
transfection of one plate of cells 18µl of FuGENE 6 was mixed with 200µl Opti-MEM R©reduced serum
media and 4.5µg of the DNA plasmid to be transfected. The transfection mixture was incubated at
room temperature for 20 minutes then added to the cells in a dropwise manner. After 24 hours the
media was refreshed. For the next 3-4 days the supernatent was collected daily, until the transfected
cells had lost viability and detached.
The supernatants were centrifuged at 3000xg for 10 minutes, passed through a 0.45 filter and ultra-
centrifuged through a 20% sorbitol cushion for 2 hours at 23,000rpm at 4◦Cusing a SW28 rotor. The
resulting pellet was resupended in RPMI 1640 (GIBCO Invitrogen) and stored at -80◦C. All HIV-1
viruses were titrated by LTR qPCR. The virus was lysed using RLT buffer, cDNA synthesised and
RT-qPCR performed as described below. The HIV-1 LTR copies/ml were determined using a stan-
dard curve generated from qPCR during the same run, of a serially diluted virus sample of known copy
number. SIV3+ virus was titrated by RT-ELISA (Roche, Product code: 11468120910).
2.5 UV inactivation of HSV-1 and HIV-1
HSV-1 or HIV-1 was inactivated by exposure to UV light, at a distance from the light of 10cm, for 10
minutes, in a sterile environment. UV-inactivation of HSV-1 and HIV-1 were confirmed by plaque assay
on vero cells or LTR qPCR following macrophage infection, for HSV-1 and HIV-1 respectively.
2.6 Macrophage infections
6 days post isolation, or 2 weeks following HSV-1 infection, macrophages were infected with HIV-1
diluted to various concentration in RPMI, in the presence of 3ng/ml of SIV3+ (vpx). The inocula-
tion volume was 500µl and the media was replaced with RPMI + AB serum 6 hours after infection.
Macrophages were infected with HSV-1 either 6 days post isolation, or 6 days post infection with vari-
ous concentrations of HIV-1 in the presence of vpx. The estimated dose of HSV-1 for each infection was
calculated as the plaque forming units of HSV-1, as titred on vero cells, per macrophage (pfuvero/cell).
Macrophages were inoculated with the desired dose per macrophage of HSV-1, in a volume of 200µl
or 500µl of RPMI supplemented with 10% FCS, for 96 well or 24 well plates respectively. 1 hour post
inoculation, the inoculation media was replaced with RPMI supplemented with 10% FCS. During the
establishment of a latent HSV-1 infection, the media was replaced every 3 days.
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2.7 Viability
Cell viablity was assessed with the alamarBlue assay (AbD Serotec, Cat. No. BUF012B) (378).
Macrophages or 293T cells in a 24 well plate were washed twice with PBS and the media replaced
with with 500µl of RPMI suplemented with 5% AB serum and 10% alamarBlue R©. The cells were in-
cubated at 37◦CC for 3 hours. 100µl of the media was collected from each well simultaneously, placed
in individual wells of a flat bottom 96 well plate and the relatively absorbency of the media at 570nm
and 595nm measured in a spectrometer. These values were used to calculate the percentage of ala-
marBlue that had been reduced by the cells, a value linearly correlated with the number of viable cells
in each well. First, the correction factor R0 was calculated:
R0 =
AOLW
AOHW
Where:
AOLW = Absorbance of AB in media - Absorbance of media only
AOHW = Absorbance of AB in media - Absorbance of media only
Which can then be used to determine the percentage difference between treated and control cells:
X = TALW−(TAHW×R0)CALW−(CAHW×R0) × 100
Where:
X = Percentage difference between treated and control cells
TALW = Absorbance at lower wavelength (i.e. 570nm), test well, minus the media blank
CALW = Absorbance at lower wavelength (i.e. 570nm), control well, minus the media blank
TAHW = Absorbance at higher (i.e. 595nm) wavelength, test well, minus the media blank
CAHW = Absorbance at higher (i.e. 595nm) wavelength, control well, minus the media blank
R0 = Correction factor
2.8 Lysis
Cell lysis was assessed by LDH ELISA. The supernatents were collected from macrophages either prior
to infection at various time points post infection with HSV-1, and assessed for the presence of LDH by
ELISA. The concentration of LDH per sample was expressed as a percentage of the concentration of
LDH in the supernatant of a sample collected following complete cell lysis resulting from the addition of
a lysis buffer. In this way, the percentage of cell lysis in the HSV-1 infected macrophages was calculated.
2.9 Nuclei counting and morphology
HSV-1 infected or mock infected macrophages in a 96 well plate were fixed with 4% PFA. The nuclei
were stained with DAPI (1:2400) (Cell Signalling Technology R©, Cat. No. 4083) for 5 minutes and
the of cells plate imaged using a high-throughput immuno-fluorescent microscope. Metamorph image
analysis software was used to count the number of nuclei per well of the plate, as well as the average
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intensity and area of each nuclei. These data were converted from txt files into fcs files (379), and
analysed using flowJo.
2.10 FACS
To assess plasma membrane integrity of HSV-1 infected cells, macrophages were mock infected or
infected with HSV-1-ICP0-YFP and detached from the tissue culture plates 6hpi by trypsinisation for
45 minutes, following which they were incubated with florescent labelled Annexin-V before FACS.
2.11 RT-qPCR
HSV-1 infected, HSV-1/HIV-1 co-infected or mock infected macropahges were lysed and the Qiagen
RNAeasy plus kit (Cat. No. 74136) used to extract and purify RNA from the cell lysates. The RNA was
DNase treated (Life Technologies, Turbo DNA-free kit, Cat. No. AM1907) to remove contaminating
DNA from the sample. cDNA was synthesized from the RNA using the qScript cDNASupermix kit
(Quanta BioSciences, Cat. No. 95047-025) and quantitative (q)PCR for selected genes performed
using ABI Prism 7000 (Applied Biosystems) and specifically designed primers and probes (Sigma-
Aldrich), in the case of HSV-gB, GAPDH, IP10, or TaqMan inventoried assays (IFI16 (Hs00194261
m1), RIG-I (Hs00204833 m1) and LTR (Pa03453409 s1) using ABI Prism 7000 (Applied Biosystems).
Transcript levels were quantified by the 2-∆∆C+ method and normalization to GAPDH expression.
2.12 Immuno-florescence
HSV-1 infected, HSV-1/HIV-1 co-infected or mock infected macropahges in a 96 well plate were fixed
with 4% PFA, blocked and permeabilised with 10% goat serum/Triton 100x for 30mins, then incubated
at 4◦CC overnight with primary antibody. The cells were washed three times with PBS, and incubated
for 1 hour with the secondary antibodies PBS supplemented with 10% goats serum. The nuclei were
stained with DAPI (1:2400) (Cell Signalling Technology R©, Cat. No. 4083) for 5 minutes and the of
cells plate imaged using a high-throughput immuno-fluorescent microscope. Immuno-flourscent images
were analysed using ImageJ/Fiji and Metamorph image analysis software. Data processing was done
using R scripting and flowJo. The primary antibodies used were mouse anti-ICP4 (ab6514, 1:1000) and
mouse anti-ICP0 (ab6513, diluted 1:10,000). The secondary antibodies used were Alexa555 anti-mouse
(1:1000) and Alexa488 anti-rabbit (1:1000)
2.13 Virion release
To assess HIV-1 virion release, the supernatents were collected from HSV-1 infected, HSV-1/HIV-1
co-infected or mock infected macropahges, and the cell-free HIV-1 gag (p24) concentrations quantified
by ELISA with recombinant standards (kit version 9.6, from AIDS Vaccine Programme, National Cancer
Institute- Fredrick). Intracellular detection of p24 was performed as previously described (9,376).
To assess HSV-1 virion release, the media was removed from HSV-1 infected, HSV-1/HIV-1 co-infected
or mock infected macrophages, the cells washed 3 times with PBS and replaced with fresh media. After
24 hours the supernatents were and assessed from the presence of infections HSV-1 virion by plaque
assay on vero cells.
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2.14 Western blot
Macrophages in 24 well plates were lysed using SDS sample buffer. The samples were boiled for 5
minutes then passed through a needle. The homogenised samples were then loaded into a NuPAGE
12% gels, 1.0mm width (Cat. No. NP0343BOX), immersed in NuPAGE sample buffer along with
a protein ladder (BioLabs, Cat No. P7711S). The samples were run for 30 minutes at a 100V. The
proteins were then transferred from the onto a nitrocellulose membrane immersed in NuPAGE transfer
buffer. The membranes were washed, blocked overnight at 4◦Cin milk then stained for ICP4 or actin.
2.15 Blocking the type I IFN receptor
Macrophages were incubated in media containing a mouse monocolonal antibody against human
IFNα/β receptor chain 2 (MMHAR-2) (PBL Interferon Source, Cat. No. 21385-1). After 1 hour
the macrophages were stimulated with recombinant type I IFN or infected with HSV-1, in the presence
of the blocking antibody.
2.16 Detection of caspase activity
Macrophages or HeLa cells were infected with HSV-1 or stimulated with staurosporine. After 6 or 24
hours the macrophages were incubated in media containing 10µM CaspACE FITC-VAD-FMK in situ
marker (Promega, Cat. No. Promega) for 30 minutes. The cells were then fixed, stained with DAPI
and imaged.
3 HSV-1 infection of macrophages
3.1 Introduction
In this chapter, I characterize HSV-1 infection of human macrophages, focusing on whether or not HSV-
1 can establish a productive, lytic infection and the nature of the host cell response to the infection.
As important cells of the innate immune system (5–7), macrophages are particularly relevant to the study
of host pathogen interactions. HSV-1 is widely used to elucidate general principles of pathogen sens-
ing and innate immune responses (190), and readily infects macrophages (197,230–235). HSV-1 therefore
provides an ideal tool with which to investigate host-pathogen interactions within macrophages. Addi-
tionally, macrophages are known to play a role in HSV-1 disease (11–13). Consequently, understanding
the HSV-1 and macrophage interaction will provide insights into both macrophage immunology and
HSV-1 virology relevant to in vivo infection.
Whilst the ability of HSV-1 to infect macrophages has long been established, there remains considerable
disagreement regarding whether or not the infection is lytic, productive and/or induces a type I IFN
response. I address these questions using the following experimental approaches:
First, I use the SC16 strain of HSV-1 which was originally isolated from an oral HSV-1 lesion (380). Pre-
vious investigations of HSV-1 infection of macrophages have used a range of laboratory strains. HSV-1
is less prone to genetic mutation in vitro than other herpesviruses, but there are still significant differ-
ences between clinical and laboratory strains (154,187). SC16 has a greater ability to cause pathogencity
in a range of HSV-1 disease models compared to other widely used strains (381) and is therefore more
clinically relevant.
Second, I assess the expression of a range of HSV-1 genes in order to investigate infection within my
model. HSV-1 infection of macrophages has been previously demonstrated at both the transcript and
protein level (233,235). However, rarely has more than one gene or protein been assessed in an individual
study. I evaluated expression of the IE proteins ICP0 and ICP4, the early gene DNA Pol, the leaky late
gene gB and the late and latency gene LAT. The protein products of these genes are multifunctional. gB,
for example, is a fusion protein that primarily functions to facilitate entry of the virion (382–386) but which
also contributes to HSV-1 immune evasion (387,388) (Table 10). ICP0 is an IE protein that facilitates
HSV-1 gene expression and interacts with the host immune system (389). It is not necessary for infection
but plays a key role in the establishment of and reactivation from latency (390–393) (Table 11). ICP4
is another IE protein involved in transcription tranactivation. DNA pol is the enzyme responsible for
replicating the viral genome. LAT is the only gene product expressed during latency and may have a role
in promoting cell survival and facilitating reactivation from latency. Assessing the expression of a range
of HSV-1 genes, expressed at different time points in the viral replication cycle, should establish if and
how HSV-1 replication progresses in macrophages. In particular, expression of ICP0, ICP4, gB, DNA
Pol and LAT were chosen as their expression can be used as markers of different stages of the HSV-1
replication cycle. I also assess de novo production of infectious virions. Virion production by HSV-1
infected macrophages has only been demonstrated by a few groups (197) and remains controversial (394).
Third, I measure the type I IFN responses in HSV-1 infected macrophages by quantifying the expression
of a number of ISGs. In previous reports of HSV-1 infection of macrophages, the type I IFN response
has been investigated by measuring IFNα production and ifnb transcription (191,197,242–244,395), an ap-
proach that has produced conflicting data. This is potentially due to cytokines from the cells used to
produce the virus contaminating the virus stocks, in particular macrophages are very sensitive to IFN-β.
Another explanation is the transient nature of ifnb gene up-regulation. Therefore, to reduce the risk
of contamination with cellular cytokines, I produce HSV-1 in vero cells, a well characterized kidney ep-
ithelial cell line originally extracted from the African green monkey in 1962, and used to produce a wide
variety of viruses and vaccines (396). Vero cells lack the capacity to produce type I IFN (397). I also purify
the virus by passing it through a sorbitol cushion, as has been previously demonstrated (398). Addition-
ally, I assess the transcript levels of a range of ISGs, including IP10, IFI16, RIG-I and IPS-1, over time.
IP10 up-regulation is known to be particularly stable following IFN-β stimulation (9).
Finally, I quantify cell death by a variety of methods, including assessment of the viability, lysis, nuclear
count and membrane permeability of macrophage cultures infected with HSV-1. The mechanisms by
which HSV-1 induces cell lysis have been relatively neglected by investigators. There is no consistency
in the literature even regarding whether or not HSV-1 causes apoptosis in tissue culture cells such as
HeLa cells, let alone macrophages (399,400). Therefore, I attempt to establish the mechanism of cell
death in HSV-1 infected macrophages by using inhibitors of specific cell death pathways.
The objectives of this chapter are as follows:
1. To establish if macrophages can be productively infected with HSV-1 by assessing IE, E and L
gene and protein expression, virion production and cell survival.
2. To investigate the mechanisms by which HSV-1 may induce macrophage death.
3. To establish if HSV-1 infection up-regulates type I IFN in macrophages, and to begin to investigate
the mechanisms by which this may occur.
3.2 Results
3.2.1 HSV-1 infects macrophages
Human monocyte derived macrophages, differentiated from adherent PBMC using M-CSF (Fig.9),
were exposed to HSV-1 and assessed for HSV-1 gene and protein expression (Fig.10). The IE proteins
ICP0 and ICP4 were expressed within 6 hours, as shown by immuno-florescent staining (Fig.11a and
Fig.11b), western blot (Fig.12a) and FACS (Fig.12b [1-way ANOVA, p≤0.0001]). The percentage of
macrophages positive for HSV-1 IE protein was dose dependent and saturated at approximately 50-60%
(Fig.12c [1-way ANOVA, p≤0.0001] and Fig.12d [1-way ANOVA, p≤0.0001]).
HSV-1 infected macrophages also expressed HSV-1 early and late genes. gB transcript and protein
was dose dependent and observed within 6 hours of infection (Fig.13a, Fig.13b [ 1-way ANOVA,
p≤0.0001], Fig.13d and Fig.13e [1-way ANOVA, p≤0.0001]). The expression of the cellular house-
keeping gene GAPDH was unaffected, except following infection with a very high MOI (Fig.13c [t-test,
0.01<p≤0.05]). gB and HSV-1 DNA Pol expression were detectable as early as 2hpi and increased in
a time dependent fashion (Fig.13e [2-way ANOVA, p=0.0004], Fig.14a [2-way ANOVA, p=0.0389]).
LAT expression did not increase in a time or dependent manner (Fig.14b [2-way ANOVA, p=0.4329]).
3.2 Results 34
HSV-1 gene expression has previously been shown to be dependent on NF-κB activation (401). NF-κB
was activated within HSV-1 infected macrophages in a HSV-1 dose dependent manner (Fig.14c [2-
way ANOVA, p≤0.0001]). NF-kappaB expression could be inhibited in either HSV-1 infected or LPS
stimulated macrophages using a specific small molecule inhibitor (Fig.14c [2-way ANOVA, p≤0.0001]).
Inhibiting NF-κB decreased HSV-1 E and L gene expression (Fig.14d). HSV-1 late gene expression could
be eliminated by coating the HSV-1 virions with soluble heparin prior to inoculation of the macrophage
cultures, so as to prevent virion entry (Fig.15a and Fig.15b) (402,403). HSV-1 late gene expression was
also sensitive to acyclovir (Fig.15c [2-way ANOVA, p≤0.0001]). Importantly, I confirmed that the RNA
used for qPCR was not contaminated with viral DNA (Fig.15d).
3.2.2 HSV-1 infection induces a type I IFN response
IP10 is widely recognised as an ISG. I confirmed that IP10 is up-regulated in macrophages in response to
stimulation with type I IFN, DNA or RNA (Fig.16a). HSV-1 infection of macrophages up-regulated IP10
in both a dose and time dependent fashion as compared to the effect of UV-HSV-1 stimulation (Fig.16b
[2-way ANOVA, p≤0.0001]). IP10 up-regulation in response to both IFN-β and HSV-1 infection was
dependent on engagement of the IFNR (Fig.16c [2-way ANOVA, p≤0.0001] and 16d [2-way ANOVA,
p≤0.0001]). HSV-1 infection of macrophages also up-regulated the ISGs IFI16, Mda5 and IFN-β
(Fig.16e). RIG-I up-regulation was not significant. Inhibiting NF-κB inhibited HSV-1 dependent up-
regulation of IP10 (Fig.16f [2-way ANOVA, p≤0.0249]).
3.2.3 HSV-1 productively infects macrophages
HSV-1 productive infection of epithelial cells results in virion release and cell death (151). I investigated
whether this was also the case for HSV-1 infection of macrophages. I assessed cell death in HSV-1
infected macrophages by three methods: measuring cell metabolic activity with the alamarBlue assay,
determining cell lysis by LDH ELISA and using nuclear counting as a measure of cell number (Fig.17a).
The alamarBlue assay an assay of metabolic activity that assesses cell death by exploiting the fact that
in a population of cells cultured in media containing alamarBlue, the rate of alamarBlue reduction is
linearly related with the number of viable cells within a cell population. This is the case within a range of
approximately 4 orders of magnitude, as demonstrated with HEK293T cells (Fig.18a). As measured by
this assay, macrophages infected with HSV-1 lost viability by 48hpi at high but not low MOIs (Fig.18b).
LDH release, used as a measure of cell lysis, was also observed 48hpi at high MOIs (Fig.18c). Death did
not occur following exposure of macrophages to UV-HSV-1 (Fig.18b and Fig.18c) and was sensitive to
acyclovir (Fig.18e and Fig.18f). HSV-1 infection of macrophages resulted in production of viable virions,
as early as 24hpi and at both medium and high MOIs, in a time dependent manner (Fig.18d [1-way
ANOVA, p=0.00635]). Nuclei counting is a more sensitive measure of cell death than the alamarBlue
or LDH assay. Cell number as determined by this method was reduced within 6 hours of infection
with HSV-1. This was HSV-1 dose dependent and occurred following even medium doses of HSV-1
(i.e. at an MOI of 10) (Fig.19a). HSV-1 dependent cell death assessed by this measure was also dose
dependent (Fig.19a [1-way ANOVA, p=0.0059]) and sensitive to acyclovir (Fig.19b), indicating that
replicative infection was necessary for this effect.
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3.2.4 The membrane permeability of HSV-1 infected macrophages
Activation of cell death pathways can be detected by assessing the plasma membrane integrity of
cells by flow cytometric quantification of Annexin-V (404). Annexin-V stains cells that are necrotic,
pyroptotic or apoptotic. Surprisingly, up to 30% of macrophages exposed to UV-inactivated HSV-1
encoding YFP tagged ICP0 (HSV-1-ICP0-YFP) were positive for Annexin-V staining (Fig.20a [2-way
ANOVA, p=0.0001]), despite the fact that UV-HSV-1 does not reduce macrophage viability (Fig.18b),
cause cell lysis (Fig.18c) or reduce nuclear count (Fig.19a). There was no significant effect of UV-
inactivation on the effect of the HSV-1 dependent increase in Annexin-V positivity (Fig.20a [2-way
ANOVA, p=0.1671]). At face value, these data suggest that at 6hpi, macrophages infected with
replication competent HSV-1 are neither apoptotic or necrotic, given that they appear to have intact
membranes and do not increase expression of Annexin-V on their outer membrane. However, detaching
macrophages from tissue culture plastic for FACS analysis is technically difficult and the data may
be confounded by the increased membrane permeability of the macrophages resulting from prolonged
trypsinization.
3.2.5 HSV-1 induces caspase activation
To determine if HSV-1 dependent macrophage death involves a programmed cell death pathway, HSV-1
infected macrophages were assessed for pan-caspase activation using a fluorescent intracellular indicator
of pan-caspase activity. The indicator detected caspase activation in a well-established model of apop-
tosis, staurosporine stimulated HeLa cells, but not mock-stimulated cells (Fig.20b). Caspase activation
was also observed in both HSV-1 infected HeLa cells and macrophages (Fig.20c). The percentage of
cells demonstrating caspase-activation was highest 6hpi, at a medium MOI (Fig.20d).
3.2.6 Using nuclear morphology to assess cell death
Apoptotic cells possess a unique nuclear morphology that distinguishes them from cells dying by other
programmed cell death pathways, such as pyroptosis and necroptosis. High-throughput microscopy
can give an analysis of nuclear morphology considerable power. As proof of this concept, the nuclear
morphologies of HeLa cells exposed to different conditions were analysed. HeLa cells were infected with
HSV-1 or incubated with either staurosporine or a DMSO loading control, and then stained with DAPI
and imaged. Staurosporine treated HeLa had a classic apoptotic nuclear morphology, with condensed,
small, bright nuclei and apoptotic bodies (Fig.20b). HSV-1 infected HeLa had nuclei with opposite
morphology, they were larger and dimmer than the DMSO control (Fig.20b).The DAPI stained nuclei
were individually scored for average intensity, area, integrated intensity (total intensity) and average
intensity/area ratio. A 2D density plot of the average intensity and nuclear area of all nuclei (n∼200,000)
demonstrated the existence of distinct populations of nuclei within even a mock infected population
(Fig.21a), representing different stages of cell division. The scales in this plot are arbitrary.
An apoptotic population would be expected to have nuclei with a higher average intensity/area ratio
than a non-apoptotic population. Indeed, the nuclei of cells within a population of HeLa cells incubated
with staurosporine, had either the same average intensity/area ratio value as control HeLa cells or
a high ”apoptotic” average intensity/area ratio (Fig.21b). In line with not being apoptotic, HSV-1
infection decreased the average intensity and increased the area of the HeLa nuclei. Consequently, the
probability density of the average intensity/area ratio for these cells was shifted to the left compared
to the DMSO control. HSV-1 infected HeLa are therefore not apoptotic and have nuclei with a more
necrotic-like morphology.
There were also multiple nuclear morphology types within a macrophage population exposed to HSV-
1 (Fig.21d). At 24hpi, a scatter-plot of nuclear area and nuclear ICP4 average intensities of all the
macrophages in an experiment (including unstained control cells) revealed 3 distinct populations of
cells (Fig.21c):(1) the unstained control population, (2) an ICP4− population with a background level
of non-specific staining and (3) an ICP4+ population of cells. The cells exposed to HSV-1 are shown
in blue. Furthermore, a 1D density plot of nuclear intensity over nuclear area revealed that at a high
MOI a greater proportion of macrophages have small, dense nuclear compared to mock infected, and at
low MOI (1-10pfuvero/cell) (Fig.22a). Furthermore, the plot shows that a population of macrophages
exposed to HSV-1 had a larger and less dense nuclei morphology than macrophages exposed to UV-
HSV-1 (Fig.22a), indicating that at low MOI macrophages infected with HSV-1 are not apoptotic. This
is shown more clearly by plotting the percentage of nuclei within the upper left or lower right quadrants
of the scatter plot (Fig.22b [2-way ANOVA p=0.0007] and Fig.22c).
3.2.7 The mechanism(s) of HSV-1 dependent macrophage death
Small-molecule inhibitors of apoptosis, pyroptosis and necroptosis were assessed for their ability to
prevent HSV-1 dependent cell death (Fig.23a). 48hpi, none of the inhibitors protected macrophages at
high MOIs of HSV-1 infection (Fig.23b) and all of the inhibitors significantly protected macrophages
at a low MOI (1pfuvero/cell). In between these extremes, only the necroptosis inhibitor completely
protected macrophages from HSV-1 dependent death, whilst the apoptosis and pyroptosis inhibitors
both provided only partial protection.
Necroptosis can be induced by type I IFN. Exposure of macrophages to type I IFN caused a small amount
of macrophage death in a dose dependent manner (Fig.23c [2-way ANOVA, p≤0.0001]) and blocking
the type I IFN response partially reduced HSV-1 dependent death (Fig.23d [2-way ANOVA, p≤0.0001]).
Finally, inhibiting NF-κB signalling also increased cell survival of HSV-1 infected macrophages (Fig.23e).
These data indicate that HSV-1 dependent macrophage death is partially dependent on activation of a
type I IFN response and requires replicative infection.
3.3 Discussion
In this chapter I have established that HSV-1 productively infects macrophages. Macrophages exposed
to HSV-1 express IE, E and L genes and proteins in a time and dose dependent fashion and nascent HSV-
1 virions are produced within 48 hours of infection. HSV-1 infection of macrophages can be inhibited
by soluble heparin and is sensitive to acyclovir and requires NF-κB activation. These data suggest
that HSV-1 infection of macrophages mirrors HSV-1 replication in vero cells. However, macrophages
were shown to be less permissive to HSV-1 than vero cells. A higher dose of HSV-1 was required to
infect the same number of macrophages as vero cells, and HSV-1 infection of macrophages saturated
at approximately 50-60%. This may be because monocyte derived macrophages are not a homogenous
population, in the way that tissue cell lines such as vero cells are, and that within a population of
macrophages some cells are unable to support HSV-1 infection, potentially because they do not express
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HSV-1 entry receptors. This possibility could be assessed by staining macrophages for known HSV-1
receptors such as HVEM and nectin-1/2 (405). Alternatively, as sentinel cells of the innate immune
system, macrophages may resist HSV-1 replicative infection, for example by undergoing cell death or
mounting a type I IFN response.
3.3.1 Cell death
I have demonstrated that HSV-1 replicative infection of macrophages induces cell death, and have
described some of the cellular mechanisms involved. Cytopathic effect (CPE) has been previously
observed in HSV infected primary human monocytes (230,234), U937s (238,246), THP-1s (234,247,248) and
mouse peritoneal macrophages (249), but this is the first description of the mechanisms by which HSV-1
cell death occurs in human macrophages. These mechanisms are complex and given the diverse array of
pro-death and anti-death signalling events that HSV-1 infection activates in other cell types, this is to be
expected. HSV-1 dependent cell death in macrophages requires replicative infection, involves both the
pyroptotic and necroptotic pathways and is partially dependent on NF-κB activation and engagement
of the IFNR.
Caspase-1 activation and pyroptosis has been demonstrated in HSV infected melanoma cells (223). On
the other hand, a number of studies have failed to observe IL-1β release following HSV-1 infection (406),
the presence of which is generally considered a marker of pyroptotic death. However, it is possible
for caspase-1 activation, inflammasome formation, and pyroptosis to occur in the absence of IL-1β
release (138). In fact IL-1β activation and induction of macrophage cell death are orchestrated by distinct
inflammasome complexes (407), the first of which contains ASC and caspase-1 that has under-gone
autoproteolysis, the second lacking ASC and auto-proteolytically processed caspase-1 (407). An inability
to detect IL-1β as a component of the HSV-1 secretasome does therefore not rule out pyroptosis as
a mechanism of HSV-1 dependent cell death. Pyroptosis can be activated by AIM2, a dsDNA sensor
known to detect HSV-1 (223), and this may be how HSV-1 activates caspase-1 in macrophages. To
confirm this, RNAi could be used to knock-down AIM2 expression in macrophages prior to HSV-1
infection.
It has been previously suggested that HSV dependent cell death in monocytes involves necroptosis (224).
U937 cells infected with a ICP4 and US3 mutant strain of HSV-1 under went cytolysis susceptible
to necroptotic inhibitors (224). This mirrors HSV-1 dependent macrophage death. Necroptosis can be
activated by an array of stimuli, including dsDNA, cytoplasmic RNA and type I IFN (408–412), any of
which could be the PAMPs that induce necroptosis during HSV-1 infection. It would be interesting to
determine whether isolated HSV-1 DNA and/or RNA can activate necroptosis in macrophages.
The type I IFN response to HSV-1 infection has also previously been linked with HSV-1 dependent cell
death. U937s infected with a mutant strain of HSV lacking the gene US3 undergo apoptosis that is
correlated with IRF3 activation (413). However, no study has previously shown that HSV-1 cell death in
macrophages can be reduced by blocking the IFNR.
The mechanisms of HSV-1 dependent macrophage death could be further elucidated by high-throughput
immunoflourescent staining. This allows single-cell analysis to confirm that cells expressing HSV-1 genes
are the ones that undergo cell death. The formation of the inflammasome and the necrosome within
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HSV-1 macrophages could also be confirmed by using immuno-florescence to determine the localisation
of the components of these intracellular structures. It could also be investigated whether any HSV-1
factors associate with the inflammasome or necrosome. In addition, mutant HSV-1 viruses could be
used to assess whether any HSV-1 encoded factors either promote or inhibit macrophage death. LAT,
for example is known to protect neurons from apoptosis, whereas ICP0 promotes cell death.
It is unclear whether HSV-1 dependent macrophage death would be beneficial or detrimental to the
host in vivo. Cell death can favour the host by eliminating viral reservoirs and activating the immune
system (119–123), or favour the virus by facilitating virion release from host cells (130). Indeed, a number
of HSV-1 proteins promote cell survival early during infection but activate apoptosis late on during
infection, around the time of nascent virion production (414–416). Necroptosis in particular is considered
a ‘back-up’ option for cell death that occurs only when apoptosis is suppressed, suggesting that either
HSV-1 is able to inhibit apoptosis in macrophages or that macrophages are resistant to apoptotic stimuli
provided by the virus. In light of this, it would be interesting to investigate whether inhibiting HSV-1
dependent cell death would inhibit or promote HSV-1 virion release.
3.3.2 Virion production
I have demonstrated that HSV-1 infection of macrophages is productive. This has been observed by
some groups previously (197), although not by others, even in the presence of viral gene expression (235).
Differences in the cell models may account for these contradictory data. HSV-1 virion production
does appear to be sensitive to cell type, for example many groups have observed that HSV-1 can not
productively infect monocytes but can productively infect differentiated macrophages or models of dif-
ferentiated macrophages such as U937 cells treated with PMA (238–241), whereas the macrophages of
neonates, isolated from either cord blood or the placenta, are non-permissive to HSV infection (394). Ad-
ditionally, mouse peritoneal macrophages (M-Res) can not be productively infected with HSV-1 (417–422).
HSV-1 productive infection is even sensitive to the method of differentiation and, for example, cannot
be supported in U937s differentiated with all-trans-retinoic acid, DMSO or lymphokine (239). Many of
the previous investigations of HSV-1 infection of macrophages were performed in the 1980-90s, before
the routine use of M-CSF and/or GM-CSF to differentiate human monocytes into macrophages. This
may account for the conflicting observations between those reports and the present study. However,
the numerous observations of abortive HSV-1 infection in myeloid cells suggest that HSV-1 infection
of M-CSF- infected macrophages may be complex - also indicated by my observation that only 60% of
monocyte derived macrophages can be infected. It may be that a proportion of macrophages are able
to support abortive or quiescent HSV-1 infection and I investigate this possibility in the next chapter.
Whether or not HSV-1 infection of macrophages is productive has implications for the relevance of
macrophages to HSV-1 disease. Virion release is necessary for virus spread from the mucosal epithelium
to the sensory neurons and for virus transmission. If macrophages are able to support HSV-1 productive
infection they may thereby contribute to both virus dissemination and transmission. If HSV-1 can also
abortively infect macrophages without inducing cell death, this may also have important implications
in vivo, for example these cells may act as reservoirs of HSV-1 infection that can be reactivated by
external stimuli. Indeed, abortive infection in human monocytes can be re-activated by differentiation
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of the cell into a macrophage (230).
3.3.3 Type I IFN
Previous studies observed that HSV-1 infection of macrophages induces only a small amount of IFN-β
release, and that HSV-1 virion production and IE expression is sensitive to treatment with exogenous
IFN-β (197). My data suggest that HSV-1 in fact induces a dramatic type I IFN response in macrophages,
that includes up-regulation of a range of ISGs, and that HSV-1 replication proceeds regardless. It has
become increasingly evident that IFN-β release is a relatively transient event compared to ISG up-
regulation (9), and this could account for the discrepancy between these data.
Recently, another study demonstrated the up-regulation of the ISGs IFNβ, IFNλ-1, TNFα, IP-10, CCL2
and CCL3 in HSV-1 infected macrophages (191). The production of IFNβ and IFNλ-1 in response to
HSV-1 infection was dependent upon Mda5, but not on RIG-I or Pol III. The production of TNFα,
IP10, CCL2 and CCL3 was Mda5 independent. There are therefore at least two, probably multiple (423),
PRRs expressed by macrophages that are capable of detecting HSV and inducing a type I IFN and/or
inflammatory cytokine response. It is also likely that HSV encodes factors that can counteract the
effectors of this response, given that HSV-1 productive infection is able to occur despite its presence.
It is also of interest whether or not the newly identified DNA sensor cGAS is able to detect HSV-1
infection of macrophages.
The ability of macrophages to induce both ISG up-regulation and cell death in response to HSV-1
infection may have important implications for co-infecting pathogens. HIV-1, for example, is able to
infect macrophages without activating either cell death or type I IFN signalling, whilst HIV-1 replication
in macrophages is sensitive to treatment with exogenous IFN-β. Given that HSV-1 and HIV-1 can both
infect macrophages, it is of interest whether or not the HSV-1 dependent type I IFN response will
inhibit HIV-1 replication and whether HIV-1 pre-infection will inhibit the HSV-1 dependent type I IFN
response. I will address these questions in the following chapter.
3.3.4 Conclusion
I have confirmed previous observations that HSV-1 can infect macrophages. The obvious questions
that arise are whether or not macrophages present at HSV-1 lesions are infected and what role they
play in vivo infection. Mouse models of human disease have shown that macrophages are important for
the control of HSV-1 encephalitis, ocular infection and hepatitis (11–13,236). It is unclear how relevant
these data are to human infection, especially given that mouse macrophages are not even susceptible to
HSV-1 infection (417–422). However, given the importance of macrophages to innate immunity, the well-
documented presence of macrophages at HSV-1 lesions and the ability of HSV-1 to infect macrophages,
it is probable that macrophages play an influential role in HSV-1 disease. This may either be as
controllers of infection or as virus reservoirs. The main question to be answered is whether or not
this role is beneficial or harmful to the host. Further work will be needed to elucidate the role of
macrophages in human disease, however, I predict that HSV-1 encoded factors orchestrate a complex
interaction with these cells, using them for different purposes at different stages of the HSV-1 infection
cycle.
4 HSV-1 and HIV-1 co-infection
4.1 Introduction
In this chapter, I investigate the effect of HIV-1 pre-infection on HSV-1 lytic infection, and the effect of
HSV-1 super-infection on HIV-1 infection, in human macrophages. Given the clinical and epidemiolog-
ical interactions of HIV-1 and HSV-1 (336,337,366), and the potential clinical importance of macrophage
infection in vivo for both these viruses (8,252), the interaction of HIV-1 and HSV-1 at the molecular level
during HIV-1/HSV-1 co-infection of macrophages is of considerable interest. This is especially the case
given that both viruses may encounter each other in vivo in the context of macrophage infection. I
therefore assess whether pre-infection of macrophages with HIV-1 affects HSV-1 IE protein expression,
early and late gene transcription or the HSV-1 dependent macrophage death or type I IFN responses.
I also assess whether HSV-1 superinfection affects LTR transcription and HIV-1 virion release.
In the previous chapter I demonstrated that HSV-1 lytic infection of macrophages is accompanied
by cell death and a type I IFN response. HIV-1 infection of macrophages in vitro occurs without
evident cytopathology or ISG up-regulation (9), and is sensitive to treatment with recombinant type I
IFN (87,260–262). Consequently, it is of interest whether a type I IFN response to HSV-1 super-infection
will have an effect on HIV-1 infection of macrophages. Given that recombinant IFN-β reduces HIV-1
virion production and replication (87,260–262), it might be predicted that HSV-1 would also negatively
impact HIV-1 replication.
HIV-1 transcription can be activated by a range of co-infecting pathogens, including herpesviruses, and
drugs, in particular those that activate NF-κB (Table 12). HIV-1 and HSV-1 transcription employ
many of the same cellular transcription factors, and a selection of these are summarised in Table 13.
Indeed, HSV-1 infection can both activate and inhibit the cellular transcription factors involved in
HIV-1 replication, for example in the previous chapter I demonstrated that NF-κB translocates to the
nucleus during HSV-1 infection and that this is necessary for HSV-1 transcription and HSV-1 dependent
cell death to occur. However, the interaction of HSV-1 with NF-κB is context and time dependent.
Both ICP0 and VP16, for example, inhibit NF-κB activation following TNF-α stimulation or TLR
engagement (424–428). It is therefore difficult to predict what the net effect of HSV-1 super-infection on
HIV-1 infection of macrophages will be.
As shown in Chapter 2, HSV-1 dependent cell death of macrophages involves both pyroptotic
and necroptotic signalling. There is controversy over whether HIV-1 directly induces cell death
in macrophages (263). There is evidence for both HIV-1 dependent cytopathology and apoptosis in
macrophages (264,267,268) and HIV-1 mediated protection of macrophages from apoptosis (265,266). HIV-1
infected macrophages can also induce apoptosis of bystander cells (269,270). Additionally, both HIV-1
dependent pyroptosis and necroptosis have been demonstrated in T cells but not macrophages (429,430).
Therefore, it will be interesting to see whether HSV-1 dependent macrophage death is affected by HIV-1
pre-infection, in particular whether there is a shift in the cell death signalling events that occur, for ex-
ample a skewing of the response to a more apoptotic than necroptotic phenotype or whether HIV-1 is
able to prevent HSV-1 induced macrophage death in the context of HSV-1 super-infection. If this were
the case it could provide insights into the interactions of HIV-1 factors with macrophage cell death
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machinery.
A number of the restriction factors that target HIV-1 replication (431) also have activity against HSV-
1. These factors include tetherin (91), members of the ABOBEC protein family (94) and, as discussed
in Chapter 1, SAMHD1 (293,294). Both HIV-1 and HSV-1 encode proteins that can counteract these
restriction factors in certain contexts. The ABOBEC family of restriction factors, for example, is
counteracted by HIV-1 vif (98,432), and ABOBECs have activity against HSV-1 when expressed at high
levels (94), suggesting that HSV-1 may also encode an APOBEC antagonist that is effective against
physiological levels of ABOBEC protein. Tetherin is a host restriction factor that prevents virion release
by tethering nascent enveloped virions to the host cell membrane. HSV-1 glycoprotein M (gM) (91)
and virion host shut-off protein (vhs) (92) and HIV-1 vpu counteract tetherin (105). Therefore, during
HSV-1/HIV-1 co-infection of the same cell, there may be crosstalk between the strategies used by these
viruses to counteract the activity of host cell restriction factors. This may lead to enhanced HIV-1
replication, enhanced HSV-1 lytic replication or both.
The objectives of this chapter are as follows:
1. To establish the effect of HIV-1 pre-infection on HSV-1 IE, E or late gene expression, cell death,
virion release and the type I IFN response, during HSV-1 infection of macrophages.
2. To investigate the effect of HSV-1 super-infection on HIV-1 transcription and virion production
in HIV-1 infected macrophages.
4.2 Results
4.2.1 HIV-1 pre-infection does not affect HSV-1 infection
To investigate the response of macrophages to HSV-1 and HIV-1 co-infection, macrophages were first
infected with HIV-1 before super-infection with HSV-1. In detail, macrophages were infected with
single-round HIV-1 (R9 BaL ∆env) in the presence of vpx. The infection was left to reach steady state
for 6 days. The macrophages were then super-infected with HSV-1. 24 hours after infection with HSV-
1, markers of HSV-1 infection were assessed, including IE protein expression, late gene transcription and
cell death (Fig.24). HIV-1 infection was confirmed, and the efficiency of this infection was increased
by vpx, as has previously been shown (Fig.25a [2-way [ANOVA, p=0.0036]) (288). HIV-1 pre-infection
had no significant effect on HSV-1 IE protein expression (Fig.25b; 2-way ANOVA, p=0.917), early
gene expression (Fig.25c [2-way ANOVA, p=0.3145]), late gene expression (Fig.25d [2-way ANOVA,
p=0.4975]) or production of nascent virions (Fig.26a [2-way ANOVA, p=0.5119]).
There was a significant but not systematic effect of HIV-1 pre-infection on HSV-1 dependent cell death,
as assessed by the alamarBlue assay of cell metabolic activity (Fig.26b [2-way ANOVA, p=0.0020]).
However, the importance of this observation is unclear given that HSV-1 dependent cell death was
unaffected as determined by cell lysis (Fig.26c [ 2-way ANOVA, p=0.1691]) or nuclear count (Fig.26d
[2-way ANOVA, p=0.9506]).
In Chapter 2, I showed that HSV-1 infection increases the nuclear area of infected cells in a way
characteristic of non-apoptotic cell death, such as pyroptosis, necrosis or necroptosis. HIV-1 infection
at a high MOI, 100 LTR copies per cell (LTR/cell), protected macrophages from this morphological
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change. The results from a single donor are showed in Fig.27. As HSV-1 dose increases the size of
the nuclei increases. This effect is reduced as the dose of pre-infecting HIV-1 increases. Collating the
results from 3 donors, in HIV-1/HSV-1 co-infected cells a greater proportion of cells had a normal nuclear
morphology than HSV-1 infected macrophages and this effect was HIV-1 dose dependent (Fig.28b [2-
way ANOVA, p≤0.001]), whereas a lower proportion of cells had the large area, low density nuclei
characteristic of HSV-1 infection, and again this was HIV-1 dose dependent (Fig.28a [2-way ANOVA,
p≤0.0001]). These data suggest that HIV-1 infection may interfere with an aspect of cell death
signalling activated in response to HSV-1 infection. However, this effect is not sufficient to protect the
macrophages from death.
Next I tested the effect of pre-existing HIV-1 infection on the type I IFN response to HSV-1 infec-
tion. In the previous chapter I showed that HSV-1 up-regulates a number of ISGs in a dose dependent
manner. This response was maintained in the context of HIV-1 pre-infection (Fig.29a [2-way ANOVA,
p=0.0036]). HIV-1 dose had no systemic effect on IP10 upregulation in the presence of HSV-1 su-
perinfection (Fig.29a; 2-way ANOVA, p=0.8592). There was also no significant difference between
up-regulation of RIG-I (1-way ANOVA, p>0.05), Mda5 (1-way ANOVA, p>0.05) and IFN-β (1-way
ANOVA, p>0.05) (Fig.29b) gene expression by HSV-1 infection of macrophages compared to HSV-1
infection of macrophages in the context of HIV-1 pre-infection.
4.2.2 HSV-1 superinfection increases HIV-1 transcription
To determine if HSV-1 super-infection of HIV-1 infected macrophages affects HIV-1 LTR transcript levels
over time, LTR expression levels in macrophages were determined both before and after HSV-1 super-
infection. HSV-1 super-infection significantly increased LTR transcription of single-round HIV-1 in a
dose dependent manner (Fig.30a [2-way ANOVA, p≤0.0001]). UV-HSV did not affect LTR transcription
(Fig.30b; 2-way ANOVA, p=0.6293). The HSV-1 dose-dependent increase in LTR transcription was also
observed in macrophages infected with full-length HIV-1 (Fig.30c [2-way ANOVA, p≤0.0001]). This was
despite a robust dose-dependent type I IFN response to the HSV-1 infection (Fig.29a; 2-way ANOVA,
p=0.0036). In fact, recombinant type I IFN also had no significant effect on HIV-1 transcription
in the context of a single round HIV-1 infection (Fig.30a), although these data were variable and
difficult to interpret. However, as has been previously demonstrated (9,87,260–262), IFN-β stimulation of
macrophages infected with full-length HIV-1 recombinant IFN-β decreased LTR transcription compared
to HIV-1 infection of macrophages in the absence of HSV-1 or IFNβ stimulation (Fig.30c [2-way
ANOVA, p≤0.0001]).
4.2.3 HSV-1 prevents type I IFN dependent restriction of HIV-1 virion release
Next I investigated whether the increase in LTR transcription observed in HIV-1 infected macrophages
following HSV-1 superinfection, leads to an increase in HIV-1 virion release. A p24 ELISA was per-
formed on supernatents harvested from HIV-1 and HSV-1 co-infected macrophages, 24 hours after
HSV-1 infection. HSV-1 super-infection did not significantly increase HIV-1 release from HIV-1 in-
fected macrophages. However, it has previously been demonstrated that type I IFN decreases HIV-1
virion release. We confirmed this observation, IFN-β decreases HIV-1 virion release by macrophages
compared to HIV-1 virion release by macrophages not stimulated with IFN-β or super-infected with
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HSV-1 (Fig.30d [2-way ANOVA, p≤0.0001]). Given that super-infection with HSV-1 of HIV-1 infected
macrophages induces a type I IFN response, it may have been expected that this interferon response
would inhibit HIV-1 release. However, this was not the case. On the contrary HSV-1 super-infection in-
creased virion release in a dose-dependent manner (Fig.30d [2-way ANOVA, p=0.0062]). Therefore, it
appears that HSV-1 super-infection protects HIV-1 virion release by HIV-1 infected macrophages from
the HSV-1 dependent type I IFN response.
4.3 Discussion
In this chapter I have shown that pre-infection with HIV-1 does not affect HSV-1 replicative infec-
tion. HSV-1 IE, E and late gene expression is unaffected, as is virion production, HSV-1 dependent
macrophage death and HSV-1 dependent up-regulation of ISGs. HSV-1 induces nuclei morphologi-
cal changes of infected cells characteristic of non-apoptotic cell death. HIV-1 pre-infection appears to
partly protect macrophages from this effect. However, it is unclear how relevant this is, given that
HSV-1 dependent macrophage death appears unaffected. I have also shown that HSV-1 super-infection
increases HIV-1 LTR transcription in a dose dependent fashion, in macrophages infected with either
single-round or full-length HIV-1. This effect is dependent on HSV-1 replication and occurs within 24
hours of HSV-1 infection. By this time HSV-1 IE, E and late gene expression has occurred.
4.3.1 HSV-1 mediated enhancement of HIV-1 transcription
HIV-1 transcription from the integrated provirus involves both viral and cellular factors, as summarised in
Tables 7 and 8. HIV-1 transcription occurs by recruitment of the cellular RNA polymerase II (RNAPII) to
the LTR promoter. RNAPII initiates basal transcription from the LTR but then pauses after synthesis
of a short transcript that includes TAR (433). Tat binds a stem loop structure within TAR (434) and
recruits P-TEF-b. CDK9, a component of P-TEF-b (435), phosphorylates the RNAPII carboxyterminal
domain (CTD) and enables RNAP mediated productive elongation of the HIV-1 transcript (436). An
HIV-1 enhancer element in the LTR promoter can be bound by a number of cellular transcription factors
that enhance HIV-1 transcription, including NF-κB, Sp1 and NF-AT.
Previous reports have demonstrated increased HIV-1 transcription following infection with a range of
co-infecting pathogens, including herpesviruses. The KSHV IE protein ORF50 (437), for example, inter-
acts synergistically with tat to enhance LTR transcription (438,439). NF-κB is a potent transcriptional
activator of the HIV enhancer (440) and the VZV IE4 protein trans-activates LTR transcription via a
NF-κB dependent mechanism (441), whereas the EBV EBNA2 protein, important for the establishment
and maintenance of EBV latency in B cells (442), enhances LTR transcription via a Sp1 and NF-κB de-
pendent mechanism (443). NF-κB activation is also the mechanism by which HHV-6 (444,445), HBV HBX,
Mycobacterium tuberculosis Rv1168C protein (446–448), Neisseria gonorrhoeae (449–451), Cryptococcus ne-
oformans (452), Toxoplasma gondii (453) and methamphetamines (454) increase HIV-1 LTR transcription.
Given that HSV-1 activates NF-κB during replicative infection, as demonstrated in Chapter 2, this may
also be the mechanism by which HSV-1 enhances HIV-1 transcription. Unfortunately this hypothesis
is difficult to test, given that NF-κB signalling is necessary for the progression of HSV-1 infection, and
that HSV-1 replicative infection is required for the enhancement of LTR transcription. To take this
work further it will therefore be necessary to identify the HSV-1 factor or factors responsible for the
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effect.
Many HSV-1 encoded proteins interact with the host transcriptional machinery, providing multiple
candidates for the one or more involved in enhancing LTR transcription. Mutant HSV-1 strains, lacking
specific functional HSV-1 proteins, could be screened for the lack of this ability. However, here again
there is the difficulty of distinguishing a direct effect from the indirect effect resulting from reduced HSV-
1 replication. Despite its role in facilitating HSV-1 transcription, ICP0 can be ruled out as a potential
candidate, given that it appears to inhibit rather than activate NF-κB, for example in response to
TNF-α stimulation (424,425). HSV-1 glycoproteins are more promising candidates. gD, for example,
inhibits HSV-1 dependent apoptosis in U937 by activating NF-κB (455). UL31 has also been shown to
be necessary for optimal NF-κB activation (456), and is another potential candidate.
4.3.2 HIV-1 virion release and type I IFN
Increased HIV-1 transcription in response to a co-infecting pathogen or drug treatment is a commonly
observed phenomenon. Pathogen or drug mediated enhancement of HIV-1 virion release is seen less
frequently. It has been demonstrated for example in response to noradrenaline treatment (457). I did
not observe an increase in HIV-1 virion release to mirror the HSV-1 dependent enhancement of LTR
transcription, although a small significant dose-dependent effect was observed.
In line with previous studies, I observe that exposure of HIV-1 infected macrophages to type I IFN
inhibits both HIV-1 transcription and virion release (8), due to the antiviral effects of multiple ISGs such
as the retrovirus restriction factors MX2 (458),TRIM22 (459) and tetherin (105). However, I did not observe
a decrease in either HIV-1 transcription or virion release in response to an HSV-1 dependent type I IFN
response, despite this response involving up-regulation of multiple ISGs, including Mda5, IFI16, IFN-β
and IP10, and engagement of the IFNR. In fact, as described above, HIV-1 transcription increases
in response to HSV-1 infection. Therefore, it may be hypothesized that HSV-1 is able to promote
both HIV-1 transcription and virion release, either by independently activating LTR transcription and
protecting HIV-1 virion release type I IFN mediated inhibition, or by enhancing HIV-1 replication such
that the effect of type I IFN on HIV-1 transcription and virion release is masked. To investigate these
hypotheses, the type I IFN response to HSV-1 could be inhibited during co-infection, to determine if
HIV-1 virion release is enhanced by co-infection in this context.
The ability of HSV-1 to increase HIV-1 transcription during HIV-1/HSV-1 macrophage co-infection
may provide a mechanism for some of the clinical synergy between these two viruses. HSV infection
is correlated with increased HIV-1 transmission and disease severity (14,15,104,324–338). HSV-1 super-
infection of HIV-1 infected macrophages at the HSV-1 transmission site, for example the vaginal mucosa,
may enhance HIV-1 replication by protecting it from the type I IFN response mounted by the host, and
thereby enhancing HIV-1 replication within the host and increasing the risk of HIV-1 transmission.
4.3.3 HIV-1 dependent protection from changes in nuclear morphology
As demonstrated in Chapter 2, the cell death response to HSV-1 infection is complex. It occurs by a
a non-apoptotic mechanism, as indicated by the large dim nuclei of the dying cells that contrast with
the small intense nuclei of apoptotic cells (460). HSV-1 macrophage death involves both pyroptotic and
necroptotic signalling. Pre-infection with HIV-1 does not protect macrophages from HSV-1 dependent
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cell death. However, it does appear to partly protect the nuclei of these cells from morphological change.
This is perhaps not surprising, given that HIV-1 has been shown to have a complex relationship with the
cell death machinery and interacts with apoptotic, necroptotic and pyroptotic signalling (265,266,429,430).
However, it is unclear whether the effect of HIV-1 on HSV-1 induced nuclear morphology has any
functional relevance, for example whether the effect observed is the result of slightly delayed cell death
or represents a skewing of the cell death response from one pathway to another, for example from
necroptotic to apoptotic. To investigate this further, specific inhibitors of cell death signalling could be
used to see if the phenotype of HSV-1 dependent cell death reported in Chapter 2, is different in the
context of HIV-1 co-infection.
4.3.4 Conclusion
I have now established that HSV-1 can productively infect macrophages and that pre-infection with
HIV-1 has little effect on this infection. Also, that HIV-1 super-infection of HSV-1 infected macrophages
increases HIV-1 transcription. In the next chapter, I will investigate whether HSV-1 can establish a
latent infection of macrophages and whether HIV-1 super-infection has any effect on this, as well as
whether the HSV-1 pre-infection has any effect on the HIV-1 infection itself.
5 HSV-1 latency in macrophages
5.1 Introduction
In this chapter I investigated if and how HSV-1 establishes latency in macrophages, where latency is
defined as abortive infection that can be reactivated.
HSV-1 has both a lytic and latent replication cycle (151). The molecular mechanisms by which HSV-1
latent infection of neurons is thought to occur are described in Chapter 1. The ability to establish
static latent infection has significant advantages for a virus. Latency enables virus persistence within
a small host population (461). Limited or lack of viral replication reduces the cost of infection in the
context of a mutualistic interaction with the host and host survival increases the opportunities for
viral transmission (462). There is little doubt that the herpesviruses are some of the most successful
of pathogens, primarily due to their ability to persist, with occasional reactivation, throughout the
entire life of the host (461). Latency is also the reason that, although we have effective antivirals
against HSV-1, the infection remains incurable, and that there is currently no vaccine (463). Current
dogma is that α-herpesviruses such as HSV-1 and VZV only establish latency within neurons (159).
However, abortive HSV infection can be established in other cell types in vitro (Table 14) (464,465).
Given the presence of macrophages at HSV-1 lesions (250,251) and their importance for the control of
HSV-1 disease (11–13,236,237,252), HSV-1 abortive infection and reactivation within macrophages would
have profound implications for the treatment and eradication of HSV-1.
In Chapter 2, I describe HSV-1 lytic infection of macrophages. This infection proceeds as it does in
epithelial cells, with a sequential pattern of gene expression followed by virion release and cell death (151).
However, there are differences between HSV-1 lytic infection of vero cells and HSV-1 infection of
macrophages, which in combination suggest that a proportion of a macrophage population exposed to
HSV-1 may support HSV-1 abortive or latent infection. First, a higher dose of HSV-1 is required to infect
macrophages than vero cells, suggesting that a proportion of macrophages are either resistant to HSV-1
infection entirely, for example because they lack the necessary entry receptor(s), or can only support
abortive infection. Second, when exposed to HSV-1, a greater percentage of macrophages express
the IE proteins ICP0 and ICP4 than undergo HSV-1 replication dependent cell death. Again this is
suggestive of an abortive infection. IE protein expression has been observed in neurons latently infected
with HSV-1 (466) and ICP0 may play a role in maintenance of HSV-1 latency (390–392,467,468). Finally, the
intracellular localisation of ICP0 in the cytoplasm, and not the nucleus, within macrophages is unusual.
ICP0 has previously only been observed in the cytoplasm during HSV-1 latency in neurons (469) or very
late on during lytic infection (470).
Macrophages are similar in a number of ways to neurons, the canonical site of HSV-1 latent infection,
in that they are terminally differentiated non-cycling cells highly resistant to apoptotic stimuli (471–474).
Interestingly, both the non-cycling state and apoptotic resistance of neurons has been proposed to
underlie their capacity to support HSV-1 latency (221,475–477).
LAT is the only gene expressed during HSV-1 latent infection of neurons (478–480). Although it is
not essential for the establishment of latency (481), it does play a role in latency maintenance and
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reactivation (482,483). LAT is also expressed in HSV-1 infected macrophages. There are two forms of
LAT that can be stably expressed, the 1.5 kilobases (kb) stable intron and the 2.0kb stable intron (484)
(Fig.31). The 2.0kb intron is expressed at high levels during both lytic and latent infection, whereas
the 1.5kb LAT is expressed only during latency (484). These transcriptional states are distinguishable by
Northern blot analysis (479,485) but not by RT-qPCR, as the 1.5kb LAT intron is entirely encoded within
the 2.0kb intron (484). Consequently, detection of LAT in HSV-1 infected macrophages supports, but
does not prove, that HSV-1 can establish latency in these cells.
Latency is often defined as the presence of viral genomes in the absence of lytic gene expression or
virion production. Therefore, I assess lytic gene expression, virion production and LAT expression over
time in HSV-1 infected macrophage cultures. If latency is established, LAT expression would persist
whilst lytic gene expression diminished due to HSV-1 dependent macrophage death.
It could be argued that true latency is defined as abortive infection that can be reactivated. This is
certainly the definition used for current in vitro models of latency (Table 14), for example, one well
established model is to infect neurons in the presence of ACV, such that replicative infection is stalled
at viral DNA replication, and to reactivate replicative infection by withdrawing the drug (256,486,487). I
therefore attempt to reactivate abortive HSV-1 infection in macrophages. An interesting stimulus to test
in this context is HIV-1 infection, given the nature of the complex interaction between macrophages and
HIV-1 and the degree of clinical and epidemiological interaction between HSV-1 and HIV-1 (343). These
interactions are described in detail in Chapter 1. Furthermore, if macrophages are latently infected with
HSV-1 in vivo at mucosal tissue sites, HSV-1 may encounter HIV-1 during HSV-1/HIV-1 coinfection.
The objectives of this chapter are as follows:
1. To establish if macrophages can be latently infected with HSV-1 by assessing cell survival, virion
production, LAT expression and late gene expression in HSV-1 infected macrophages over time.
2. To begin to investigate the mechanisms by which HSV-1 latency in macrophages is established,
paying particular attention to the role of type I IFN.
3. To determine if HSV-1 quiescent infection of macrophages can be reactivated with HIV-1, and
to begin to investigate the mechanisms by which this may occur.
5.2 Results
5.2.1 HSV-1 latently infects macrophages
If, within a macrophage population exposed to HSV-1, a proportion of macrophages supports HSV-
1 latency whilst others support HSV-1 lytic replication, we would expect gB expression within the
population to diminish over time, as productively infected cells die. LAT expressing cells would persist
(Fig.32). Macrophages infected with a medium to low dose of HSV-1 survived until at least 2 weeks
post infection. There was no difference over a period of 2 weeks between the nuclear count (Fig.33a
[2-way ANOVA, p=0.1167]) or the level of cell metabolism (Fig.33b [2-way ANOVA, p=0.6089]) of
macrophages infected with either 2 or 20pfuvero/cell of HSV-1. Also, there was no difference in
detectable cell lysis of macrophages 2 weeks after infection with either 2 or 20pfuvero/cell of HSV-1,
compared to cell lysis 2 days after infection (Fig.33c [1-way ANOVA, p>0.05]).
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As previously observed, after 24 hours infection with HSV-1, both gB and LAT expression were high
(Fig.34a and Fig.34b). However, over a 2 week period gB expression decreased in macrophages in-
fected with HSV-1 in a time dependent manner (Fig.34a [2-way ANOVA, p≤0.0001]). gB expres-
sion had all but disappeared 2 weeks after infection with either 2pfuvero/cell (Fig.34a [1-way ANOVA,
p≤0.0001]) or 20pfuvero/cell (Fig.34a [1-way ANOVA, p≤0.0001]). LAT expression, on the other hand,
remained high over 2 weeks after infection with either 2pfuvero/cell (Fig.34b [1-way ANOVA, p>0.05])
or 20pfuvero/cell (Fig.34b [1-way ANOVA, p>0.05]). Expression of LAT did change significantly in a
time dependent manner (Fig.34b [2-way ANOVA, p≤0.0001]), but not in a systematic fashion. It went
down and then up.
GAPDH and IP10 expression levels were relatively stable over the two weeks (Fig.34c [1-way ANOVA
p>0.05] and Fig.34d [2-way ANOVA, p=0.1123]). These data suggest that a proportion of macrophages
do indeed support abortive HSV-1 infection.
5.2.2 Establishment of latency
To determine whether the establishment of HSV-1 latency in macrophages required an initial round of
productive infection, LAT and gB expression over time was assessed in macrophages exposed to HSV-1
in the presence of acyclovir (Fig.35). As shown in Chapter 2, acyclovir inhibits HSV-1 DNA replication
and lytic gene expression in macrophages. Acyclovir abolished gB (Fig.36a [2-way ANOVA, p≤0.0001])
expression, suggesting that HSV-1 replication is indeed required for the establishment of latency.
In Chapter 2, I demonstrated that HSV-1 replicative infection activates a type I IFN response. To assess
whether the type I IFN response to HSV-1 lytic infection contributed to the establishment of latency
during secondary HSV-1 infection, I used an IFNR blocking antibody during the initial HSV-1 infection
(Fig.37). Blocking the IFNR inhibited the type I IFN response after 24 hours to both HSV-1 infection
and treatment with IFN-β (Fig.38a). IP10 up-regulation was not observed over the 2 weeks following
treatment with IFN-β in the presence of the antibody compared to treatment with IFN-β in the absence
of the antibody (Fig.38a [2-way ANOVA, p≤0.0001]). However, IP10 up-regulation was observed within
a week of HSV-1 infection in the presence of the antibody compared to IP10 up-regulation after 1 day
post infection with HSV-1 in the presence of the antibody (Fig.38a [1-way ANOVA, 0.05≤p>0.001]).
This was probably due to a HSV-1 dependent type I IFN response to continued HSV-1 lytic replication
following withdrawal of the antibody after 24 hours. There was little or no significant difference between
either gB (Fig.38b [2-way ANOVA, p=0.5489]) or LAT (Fig.38c [2-way ANOVA, p=0.3674]) expression
following HSV-1 infection in the presence or absence of the blocking antibody. Unfortunately, due to
time constraints, I was unable to assess the effect of inhibiting NF-κB or blocking the IFNR during the
full 2 weeks over which latency was established.
5.2.3 Latent HSV-1 is reactivated by HIV-1
By definition, a true latent infection can be re-activated to a lytic infection. In Chapter 3, I demonstrated
that HIV-1 pre-infection has no effect on replicative HSV-1 infection, and that HSV-1 superinfection
increases HIV-1 transcription. Given the role of NF-κB signalling in both HIV-1 and HSV-1 transcription,
I attempted to re-activate latent HSV-1 from macrophages either by HIV-1 infection or LPS stimulation.
LPS is an outer membrane component of Gram negative bacteria that activates NF-κB signalling via
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TLR4 stimulation (488). LPS can reactivate other herpesviruses from latency (489) and is a very potent
stimulator of macrophages. Given the importance of NF-κB signalling in HSV-1 transcription, it may be
expected that LPS would reactivate latent HSV-1 infection of macrophages. LAT+ gB− macrophages
were stimulated either with LPS, vpx only or single-round HIV-1 with vpx, 2 weeks post infection with
HSV-1 (Fig.39). As expected, after an initial burst, gB expression decreased over time until it had all
but disappeared by 2 weeks (Fig.40a). Stimulation with LPS at this point had no effect on gB expression
(Fig.40a [1-way ANOVA, p>0.05]), but up-regulated expression of IL-6 as has been previously shown
(Fig41a [2-way ANOVA, p≤0.0001]). However, stimulating HSV-1 infected macrophages with HIV-
1 caused an increase in gB expression over a 24 hour window (Fig.40a [2-way ANOVA, p=0.0036]),
suggesting that HIV-1 can re-activate latent HSV-1 in macrophages. These data were mirrored by those
for HSV-1 DNA Pol expression over time and for the effect of HIV-1 infection on DNA Pol expression
at 2 weeks post infection with HSV-1 (Fig.40b [2-way ANOVA, p=0.0141]).
The supernatents of macrophages latently infected with HSV-1 were tested for the presence of viable
viruses, both before and after HIV-1 stimulation. Prior to HIV-1 stimulation, hardly any viable virus
was detectable in the supernatent of latently infected macrophages. After HIV-1 stimulation, viable
HSV-1 virions were released within 24hpi (Fig.40c [1-way ANOVA, 0.01<p≤0.05]). IP10 transcription
was unaffected by time (Fig.40d [2-way ANOVA, p=0.00123]) or HSV-1 re-activation (Fig.40d [1 way
ANOVA, p>0.05]), remaining high throughout.
5.2.4 HIV-1 transcription is not required for reactivation of HSV-1 latency
Exposing macrophages latently infected with HSV-1 to HIV-1 prevented HIV-1 LTR transcription
(Fig.41b [1-way ANOVA, p≤0.0001]). This was not surprising, given that HIV-1 infection is sensi-
tive to type I IFN (9) and that latently infected macrophages still displayed significant ISG up-regulation
2 weeks post infection with HSV-1 (Fig.34d). Furthermore, exposing macrophages latently infected with
HSV-1 or mock infected macrophages to UV inactivated HIV-1 (UV-HIV-1) such that no LTR transcrip-
tion was observed in the mock infected macrophages (Fig.41c), resulted in little or no reactivation from
macrophages infected with either 2pfuvero/cell (Fig.41d [1-way ANOVA, p>0.05]) or 20pfuvero/cell
(1-way ANOVA, p>0.05). Although there was a small significant systematic effect (2-way ANOVA,
p=0.444).
5.3 Discussion
In this chapter I have shown that HSV-1 can establish latency in macrophages, where latency is defined
as a quiescent or abortive infection that can be reactivated. A proportion of cells within a population of
macrophages exposed to HSV-1 support replicative infection incorporating late gene expression, virion
production, a type IFN response and cell death. Another proportion of macrophages support quiescent
or abortive infection, comprising LAT expression, no late gene expression, no virion production and a
type I IFN response. These gB−LAT+ macrophages survive for at least 2 weeks. HSV-1 latency in
macrophages is dependent on the initial round of replicative infection, as acyclovir treatment during
the first 24 hours of infection abolishes not only gB expression and cell death, but also LAT expression.
Finally, exposure of gB−LAT+ macrophages to HIV-1, and to a lesser degree UV-HIV-1, re-activates
gB expression and virion production, in the absence of HIV-1 transcription.
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5.3.1 Establishment of latency
Latent HSV-1 infection has previously been modelled in neuron cell lines and primary neurons, where
an abortive infection established in the presence of an inhibitor is reactivated by removing the inhibitor.
One such model involves infecting PC12 rat cells with HSV-1 in the presence of nerve growth factor
(NGF) (490). In this experimental system, HSV-1 DNA and LAT is detectable and there is little or no
virion production. Removal of NGF causes an increase in virion production (490). It is thought that
the ability of NGF to promote the establishment of latency is linked to its anti-apoptotic effect, in
line with the ability of promotors of apoptosis to reactivate latent HSV-1 (221,491). Another model of
HSV-1 latency is the infection of PC12 cells with HSV-1 in the presence of acyclovir (487,492). This
promotes the establishment of an infection with no detectable virus production. Latency is maintained
when acyclovir is withdrawn after 10 days (487,492). In this model, latency can be reactivated by heat
stress (487) or forskolin treatment (492). Forskolin activates adenylyl cyclase and increases the intracellular
level of cAMP (493). Another method of modelling HSV-1 latency in vitro is to infect human fetus dorsal
root ganglion (DRG) neurons with HSV-1 in the presence of an anti-HSV drug, for example the thymine
analogue (E)-5-(2-bromovinyl)-2’-deoxyuridine (BVdUrd) a , and IFN-α (477). These in vitro models of
HSV-1 latency mirror HSV-1 latency in vivo in that they can be reactivated by stress, that they involve
the expression of LAT in the absence of lytic gene expression or virion production, that LAT is not
essential for the establishment of latency and that they are sensitive to deletion of the same HSV-1
proteins, for example US5, and that these deletions can be compensated for with the expression of
LAT (494). HSV-1 quiescent infection of macrophages is similar to these previous in vitro models, in
that virion production is absent, LAT is expressed and productive infection can be reactivated. As such,
it is reasonable to term HSV-1 quiescent infection of macrophages as latency, according to how the
term is currently used in the field.
HSV-1 latent infection of macrophages as a model of HSV-1 latent infection possesses a number of ad-
vantages over previous in vitro models. Firstly, establishing a quiescent HSV-1 infection of macrophages
does not require anti-HSV-1 drugs, recombinant type I IFN or anti-apoptotic growth factors. Instead,
HSV-1 infection of macrophages appears to mirror that which occurs during HSV-1 infection of neurons
in vivo, in that there is an initial round of lytic replication, induction of innate immune responses, virion
production and cell death. As in neurons, this infection is gradually dampened, such that productively
infected macrophages die and gB−LAT+ cells persist. Consequently, HSV-1 infection of macrophages
provides a model of HSV-1 infection that includes both the lytic and latent replicative cycles, and, with
the lack of a need for anti-HSV-1 drugs, is arguably a more relevant model of HSV-1 latency than
previous experimental models.
Given the ability of type I IFN to induce HSV-1 latency in other experimental models (491), the type I
IFN response to HSV-1 infection of macrophages and the necessity for an initial round of replicative
infection required for the establishment of HSV-1 latency in macrophages, I propose a model of how
HSV-1 latency may be established in this system. Infecting macrophages with a high dose of HSV-
1 causes a close to 100% lytic infection, resulting in virion production and cell death within 48hpi.
Infecting macrophages with a low to medium dose of HSV-1 results in a less than 100% infection
(Fig.42a). Here, the infected cells undergo lytic replication. Within 6 hours they also release type I IFN
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that has a paracrine effect on the bystanding uninfected cells (Fig.42b). Nascent virions are released
after 24 hours. These infect the bystander cells in which an antiviral state has already been established
(Fig.42c). I propose that HSV-1 is unable to undergo replicative infection under these conditions and
instead establishes a latent infection (Fig.42d).
I have attempted to determine if either NF-κB signalling or IFNR engagement is necessary for the
establishment of HSV-1 latency in macrophages. However, the initial replicative infection is sensitive
to NF-κB inhibition, as demonstrated in Chapter 2, and the establishment of latency is dose dependent
on the degree of replicative infection that occurs in the macrophage culture. Therefore, it is unclear
whether inhibiting NF-κB effects the establishment of latency directly or indirectly by reducing the initial
round of replicative infection. This aspect of the infection also makes it difficult to assess the effect of
recombinant type I IFN on the establishment of latency, as replicative HSV-1 infection is also sensitive
to type I IFN. Additionally, replicative infection and the type I IFN response persists over the 2 week
period that latency is established, making it difficult to block it completely by a single intervention.
This again makes it difficult to interpret the results of these experiments.
HSV-1 latent infection of macrophages provides considerable opportunity for investigating the mecha-
nisms of latency maintenance. It could be investigated, for example, whether LAT is necessary and/or
sufficient for the phenotype, and whether it performs similar roles in macrophages as it does in neurons.
These include, protecting latently infected cells from HSV-1 superinfection (495), repressing IE transcrip-
tion (483), promoting cell survival potentially by HVEM up-regulation (496) and activation of NF-κB and
type I IFN signalling (497). The function of LAT during HSV-1 infection of macrophages could be as-
sessed using a HSV-1 mutant virus lacking the ability to express LAT (498). Additionally, HSV-1 latency
of macrophages could be further characterised. Of particular interest is whether the viral genomes in
latently infected macrophages are circularised as in latently infected neurons, how many of the popula-
tion of surviving macrophages express LAT and/or contain viral DNA and whether any HSV-1 proteins
persist in the latently infected macrophages, in particular ICP0. These questions could be addressed us-
ing immuno-florescence to detect HSV-1 protein and fluorescence in situ hybridization (FISH) to detect
HSV-1 DNA and LAT (499).
During HSV-1 infection of neurons, VP16 is restricted to the cytoplasm, and so can not activate IE
gene expression, as described in Chapter 1. It is thought that this effect is due to the non-cycling state
of neurons. It would be interesting to assess the localisation of these factors in macrophages, and to
assess the intracellular localisation of VP16 in macrophages both lytically and latently infected with
HSV-1, so as to determine if the lack of VP16 mediated ICP0 expression provides a block to HSV-1
replicative infection in macrophages.
The second block to HSV-1 replicative infection in neurons is at the ICP0 mediated expression of other
IE genes. ICP0 is required to remove the HDAC-1-CoREST-REST repressor complex from the IE gene
promoters. ICP0 can be inhibited from performing this function by being trafficked to the cytoplasm.
Consequently, the intracellular localisation of ICP0 in macrophages latently infected with HSV-1 is also
of interest.
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5.3.2 Reactivation of latency
HIV-1 mediated reactivation of HSV-1 latency is a novel observation. Methods of reacting latent HSV-1
in vitro have included heat stress (492), cold shock (465,477,500–502), exposure to inhibitory drugs or growth
factors (256,486,487,503), expression of IE proteins from adenovirus vectors (487) or UV irradiation (504). It
is of interest whether any of these stimuli could also reactivate HSV-1 latency in macrophages.
Further work is required to characterize the nature of the reactivated HSV-1 infection. I have shown
that it involves both late and early gene expression and virion release. It will be interesting to determine
whether IE proteins are expressed, or whether this part of HSV-1 replicative infection is bypassed during
reactivation in macrophages. There are precedents for this, for example within experimental models of
latency where latency is reactivated by factors that preform the action of IE HSV-1 proteins. It will
also be interesting to establish whether viral DNA replication is stalled during establishment of HSV-1
latency in macrophages and whether it is resumed during reactivation, and in connection with this,
what the form of the HSV-1 DNA takes in the latently infected macrophages, i.e. whether it is in a
circularised or linear form.
Super-infection with another virus has been shown to reactivate HSV-2 latency (464). In this experimen-
tal model, HSV-2 quiescent infection of human embryonic lung cells in vitro was reactivated by HCMV
super-infection and E gene expression (464). Both HSV-1 and HCMV IE and E protein share the ca-
pacity for both viral and cellular gene transactivation, for example by recruiting NF-κB and other host
transcription factors. HIV-1 proteins also interact with the host cell transcription machinery (Table 7).
It may be that in the context of HIV-1 reactivation of HSV-1, HIV-1 factors establish a transactiva-
tional state, for the purpose of promoting HIV-1 and cellular gene expression, that has the bystander
effect of promoting HSV-1 replicative gene expression. This is supported by a model of HSV-1 latency
whereby a general state of viral gene silencing is established and can be reactivated to gene expres-
sion by the expression of HSV-1 IE proteins (487), pro-apoptotic drugs, stress (492) or histone deacetylase
inhibitors (256).
Given that exposure to HIV-1 can reactivate latent HSV-1 from macrophages without detectable HIV-1
LTR transcription, and that UV-HIV-1 can cause partial reactivation, the ability of HIV-1 to reactivate
HSV-1 must be dependent on a component or entry process of the HIV-1 virion. The process of virion
entry itself is known to activate cells (505,506), for example by inducing membrane permutations that
activate STING (507). Therefore, a key issue to clarify in this work is whether entry of other VSV-
pseudotyped lentiviruses, virus-like particles (VLPs) or enveloped viruses, such as adenoviruses, are
capable of reactivating HSV-1 latency in macrophages. However, given that vpx, which is also delivered
via a VSV-pseudotyped lentivector, does not reactivate HSV-1, the effect of HIV-1 may be more specific
than this. The effect of empty VSV-pseudotyped lentivectors or VLPs should also be assessed as the
most appropriate control for the specificity of the HIV-1 mediated effect.
The HIV-1 p24 capsid contains two copies of the ssRNA genome tightly bound by the nucleocapsid
proteins, p6, p7, and the virally encoded RT and integrase. A matrix of p17 surrounds the capsid.
The HIV-1 accessory proteins vif, vpr and nef are also contained in the virion (508,509). Vif, vpr and nef
are all multifunctional proteins, the known functions of which are described in Table 15. Any of these
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three proteins may be responsible for HIV-1 dependent reactivation of HSV-1. Vif is essential for HIV-1
infection of its target cells (510,511). Its primary function is to prevent ABOBEC mediated restriction of
HIV-1 replication (96–104,432,512–514). HSV-1 infection is also sensitive to APOBEC cytidine deaminases
both in vitro (94) and in animal models of HSV-1 encephalitis (93), suggesting that vif may be able to
promote HSV-1 infection. However, it is unclear how this would affect HSV-1 latency. Vpr is a more
likely candidate. Vpr is not required for virus replicationT cells but enhances the ability of the virus to
infect macrophages (515,516). The functions of vpr include interacting with Sp1 to transactivate HIV-1
LTR expression (517) and reactivating HIV-1 virion production from latency (518). Sp1 is activated during
HSV-1 infection in an ICP4 dependent manner (519) and it may be that vpr is able to substitute for this
function of ICP4 in order to reactivate latent HSV-1. Alternatively, vpr may enable HSV-1 reactivation
by inducing a global transcriptionally active state within the co-infected macrophages, in the same way
that it reactivates HIV-1 virion production and increases hepatitis C virus RNA replication (518,520). Vpr
can also induce apoptosis (521,522). Apoptosis has been shown to induce HSV-1 reactivation in ganglionic
organ cultures (221), suggesting that this is another potential mechanism by which HIV-1 may reactivate
HSV-1. Additionally, both vif and vpr manipulate the cell cycle to favour HIV-1 replication (523–527).
Given the known importance of the mitotic state of HSV-1 target cells for the determination of whether
replicative or latent infection is established, these functions of vif and vpr may also contribute to HIV-
1 dependent reactivation of latent HSV-1 in macrophages. Nef enhances HIV-1 virion infectivity and
increases HIV-1 replication in T cells and macrophages (528). In contrast to vpr, nef protects macrophages
from apoptosis (529–535), a function shared by HSV-1 LAT (536–538). Indeed, another anti-apoptotic gene,
the bovine herpes virus 1 (BHV-1) latency-related (LR) gene, is able to efficiently substitute for LAT
function in HSV-1 reactivation (538). Finally, like vpr, nef is able to activate an array of transcription
factors, including AP-1, NF-κB, STAT1 and STAT3 (529,539–541). NF-κB activation can be ruled out as
a potential mechanism of HSV-1 reactivation in macrophages, given that LPS, a potent activator of
NF-κB, has no effect on latent HSV-1. Potentially, the combinatorial effect of vpr, vif and nef enables
HIV-1 to reactivate HSV-1. I would predict that the most likely mechanism is that HIV-1 capsid proteins
manipulate the infected cellular environment to produce a transcriptionally active state, that indirectly
enables HSV-1 to bypass a block to replicative infection.
5.3.3 Conclusion
Quite apart from being a novel model of HSV-1 latency, HSV-1 quiescent infection of macrophages
may be relevant to in vivo infection, where tissue macrophages may provide additional reservoirs of
infection. This would have implications for efforts to eradicate HSV-1 infection from the body and for
strategies aimed at preventing HSV-1 reactivation. However, it is likely that only a few macrophages,
for example those present at the transmission site, will be latently infected with HSV-1 in healthy
individuals. This will make it difficult to investigate HSV-1 latent infection of macrophages in vivo. A
difficulty compounded by the nature of latency itself, definitionally the lack of viral gene expression,
that has presented difficulties to herpes-virologists for decades. To further complicate issues, it is
unlikely that mouse models of HSV-1 disease will be of use, given that HSV-1 is unable to infect mouse
macrophages. It may be that methods that can track a virus infection, including the cell type that are
subsequently infected, as it progresses through the body (542) will provide novel insights into which cells
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HSV-1 can and does infect in vivo.
The ability of HIV-1 to reactivate latent HSV-1 infection of macrophages may have profound implica-
tions for our understanding of the interaction of these viruses within a co-infected individual. HIV-1
co-infection increases HSV-1/2 shedding, HSV-1/2 reactivation rates and the duration of hepatic ul-
cers (176,340,350,354–357). It has previously been thought that this is due to HIV-1 mediated disruption of
the host immune system. (343,356,357). However, it may also be that HIV-1 and HSV-1 interact directly
within host cells, and that HIV-1 is able to reactivate latent HSV-1 in macrophages at HIV-1/HSV-1
transmission sites. This may be a mechanism by which HIV-1 increases the severity of HSV-1 associ-
ated disease (366). The majority of the epidemiological studies of HSV/HIV-1 co-infection concentrate
on HSV-2. HSV-1 is now the leading cause of genital herpes in the developed world, and it is reasonable
to believe that HSV-1 will or does have the same epidemiological interactions with HIV-1 as HSV-2.
However, the current study could be extended to incorporate to HSV-2 and to investigate whether it
too can establish a latent infection in macrophages.
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6 General discussion
HSV-1 and HIV-1 co-infection of macrophages is an interesting avenue of research in regard to dissecting
the mechanisms by which the innate immune system responds to viral infection in vivo. It is also
relevant to the understanding to host pathogen interactions between these clinically significant viruses
and their target cells. Additionally, the considerable clinical interaction between HSV-1 and HIV-1 at
the population and epidemiological levels, prompts a closer examination of the potential interactions of
these viruses at the cellular and molecular level.
In this thesis, I confirm previous observations that HSV-1 productively infects human macrophages.
Previous reports have failed to extensively characterise this infection and have generally been restricted
to the measurement of only a few aspects of HSV-1 replication, in particular IE protein expression,
nascent virion production or cell death. However, it is becoming increasingly evident from investigations
of HSV-1 latency and abortive infection, that the HSV-1 replication cycle can stall following IE expression
and that the absence of cell death does not necessarily indicate a lack of productive infection. In contrast
to these previous studies, I demonstrate HSV-1 productive infection of macrophages at the levels of IE,
E and late gene expression, IE and late protein expression, nascent virion production and cell death.
This provides very clear evidence that macrophages are permissive to HSV-1 replicative infection. It
follows that tissue macrophages, at the site of HSV-1 lesions, are likley targets for the virus in vivo.
Unfortunately, this hypothesis is difficult to test, particularly because mouse macrophages are resistant
to HSV-1 infection, primary human macrophages are difficult to obtain and tissue sections of HSV-1
lesions are not readily available for histochemical staining.
HSV-1 nucleic acids can be detected in vitro by the majority of the cytoplasmic nucleic acid sensors so
far discovered. However, this was demonstrated in studies using models in which a particular receptor
of interest was over-expressed in a tissue cell line. It could be argued that these systems may not
tell us much about cytoplasmic nucleic acid sensing in vivo, except in regard to the identity of the
receptors that may or may not be involved. Indeed, it seems biologically improbable that cells express
10 or more functionally redundant receptors in vivo, as there is less negative selection against loss of
function mutations in redundant genes than other genes. It seems more likely that nucleic acid sensors
behave in a cell type and pathogen specific manner. Consequently, it is of interest whether HSV-1
infection of a immunologically relevant cell type, such as macrophages, is detected by the cell such that
a type I IFN and/or cell death response is induced. In this thesis, I demonstrate that this is indeed
that case, and that the type I IFN response to HSV-1 infection is dependent on HSV-1 replication, not
merely the recognition of components of the virion envelope. I also elucidate the mechanisms by which
HSV-1 dependent macrophage death occurs, showing that it involves multiple cell death pathways
and is partly dependent on the HSV-1 induced type I IFN response. These observations add to the
accumulating evidence indicating interaction between type I IFN and cell death pathways, as well as
the complex nature of the interaction between different programmed cell death pathways themselves.
These observations are in line with the complex and contradictory literature regarding type I IFN and
cell death responses to HSV-1 infection. My data demonstrate that there is not an easy answer to the
question ’Does HSV-1 inhibit or activate cell death signalling?’. Inhibition of one cell death response
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can lead to activation of others, and it is likely that many HSV-1 factors interact with the cellular
components of the apoptotic, pyroptotic and necroptotic pathways. Elucidating these interactions will
require extensive work. However, an important message of this thesis is that it is probably inappropriate
to consider HSV-1 cell lysis a process that is not, in some way, orchestrated by programmed cell death
pathways.
HIV-1 and HSV-1 co-infection has not previously been investigated. In this thesis I demonstrate that
HIV-1 pre-infection has no effect on HSV-1 productive infection of macrophages. This is perhaps not
surprising given that HIV-1 infection of macrophages is relatively silent in terms of cell activation.
HSV-1 super-infection of HIV-1 infected cells however, leads to an increase in HIV-1 transcription.
Additionally, HIV-1 virion release is not restricted by an HSV-1 dependent interferon response, as it is
by recombinant type I IFN, suggesting that HSV-1 is able to protect HIV-1 release from type I IFN
restriction. These data are interesting from the point of few of the observed clinical synergy between
HSV-1 and HIV-1. It may be that HSV-1 increases HIV-1 transmission rates and disease, not merely by
recruiting target cells to the mucosal transmission site, but by increasing or protecting HIV-1 replication
within macrophages. Again, this is a difficult hypothesis to test in vivo.
In this thesis I show that HSV-1 can latently infect macrophages. HSV-1 latent infection of cell types
other than neurons or neuron cell lines, has not previously been demonstrated. I prove latency in the
methods accepted as standard by the field. These are namely the presence of HSV-1 LAT in the absence
of lytic gene expression or virion production, and the ability for lytic gene expression to be reactivated.
HSV-1 latency in macrophages can be reactivated by HIV-1. It is of considerable interest whether other
lentivectors or viruses also have this ability. Investigation into this should also provide insights into the
mechanism(s) by which reactivation is achieved.
HSV-1 latent infection of macrophages has significant implications for our understanding of HSV-1
disease and latency in vivo. It is difficult to assess whether tissue resident macrophages support HSV-1
latency, but this thesis does bring into question the dogma that neurons are the only reservoirs of HSV-1
during clinical latency. The implications of this for our understanding of HSV-1 disease, treatment and
eradication are likely to be significant. Additionally, the model of HSV-1 latency provided by HSV-
1 infection of macrophages is potentially the best model of HSV-1 latency in vivo to date, in that
artificial interventions, such as infection in the presence of an anti-HSV-1 drug, are not necessary for
the establishment of latency. HSV-1 infection of macrophages therefore potentially provides a very
useful tool for investigating the mechanisms by which HSV-1 latency is established to researchers in
the field.
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Figure 1: Cytoplasmic PRRs and the type I IFN response.
Numerous nucleic acid sensors detect RNA and/or DNA in the cytoplasm. Synthetic CpG DNA is detected by
DDX36 and DDX9, whereas synthetic RNA poly(I:C) is detected by a complex of DDX1, DDX21 and DDX36.
[2] DDX36 and DDX9 activate the MyD88 signalling pathway, involving MyD88, IRAK4, IRAK1 and IKK-α,
leading to phosphorylation, dimerisation and nuclear translocation of IRF7. [3] IRF7 promotes transcription of
the IFN-α genes. [4] DDX1-DDX21-DDX36 activates a MyD88-independent signalling, involving TRIF, TRAF2,
TRAF3 and IKK-, leading to phosphorylation, dimerisation and nuclear translocation of IRF3. [5] IRF3 can also
be activated by the STING signalling pathway, involving TRIM56, TBK1 and IPS-1/MAVS, and resulting in an
IRF3 activating complex within the mitochondrial membrane. The RNA sensors RIG-I and Mda5 and the DNA
sensors DDX41, IFI16, H2B and ZBP-1 all signal this way. [6] The DNA sensor LRRFIP1 activates IRF3 via
STING-independent β-catenin signalling. [7] Following nuclear translocation, IRF3 activates transcription of the
IFN-β gene, ifnb. IRF3 activation can also lead to transcription of ISG, independently of IFN-β transcription.
[8] IFN-β is released from the cell and binds type I IFN receptors on the cell surface, in an autocrine or paracrine
fashion. [9-10] Ligation of the IFNR activates STAT1/STAT2 phosphorylation, translocation to the nucleus and
STAT1/STAT2 dependent induction of ISG and IFN-α gene transcription.
Figures 116
Figure 2: Initiation of pyroptosis.
[1] A variety of danger signals induce formation of a variety of inflammasome complexes. The NLRP3 and
NLRP1 inflammasomes are activated by rupture from phago-lysosomes of, for example, crystals and asbestos.
NLRP1 is also activated by lethal anthrax toxin and NLRP3 by binding of ATP to the PX2Y receptor. The AIM2
inflammasome is activated by cytosolic dsDNA derived from bacteria and viruses. The NLRC4 inflammasome is
activated by detection of flagellin by the T3SS receptor. [2] Inflammasome complexes are multiprotein oligmers
consisiting of caspase-1, ASC and either a NLR or AIM2. They can also contain caspase-5, NAIPs or CARD8 in
the cases of the the NLRP1, NLRP3 and NLRC4 inflammasomes respectively. [3] Formation of an inflammasome
leads to cleavage of pro-caspase-1 into caspase-1. Caspase-1 cleaves pro-IL-1β within the cytoplasm into IL-1β.
[4] IL-1β is released from the cell.
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Figure 3: Initiation of necroptosis.
[1] Necroptosis can be initiated by ligation of death receptors, such as TNFR, on the cell surface. [2] Binding of
TNF-α to TNFR leads to the formation of the multi-protein TNFR complex I at the cytoplasmic domain of the
receptor, containing TRAF2, TRAF5, TADD, cIAPs and RIP1. cIAPs poly-ubiquintinate RIP1. [3] Ubiquinated
RIP1 recruits TBK1, TAB2 and TAB3, leading to the initiation of NF-κB signalling. [4] TNFR complex II
is formed following internatization of ligated TNFR and the recruitment of RIP3, FADD and caspase-8. [5]
Caspase-8 degrades RIP1 and RIP3 and thereby initiates extrinsic apoptosis. [6] If caspase-8 is inhibited RIP1
and RIP3 are phosphorylated, form the necrosome complex and initiate necroptotic signalling.
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Figure 4: The replication cycle of HSV-1.
HSV-1 transmission occurs at the mucosal epithelium. Following virion entry in the epithelium cells, HSV-1
IE, E and late gene expression and viral DNA replication occurs, followed by release of nascent virions. [2]
Infectious virions produced at the site of transmission enter nerve termini of the peripheral nervous system and
virial capsids are transported up the axon to the cell body and nucleus (543). [3] HSV-1 lytic replication occurs
for a short time in the sensory neurons before latency is established. [4] HSV-1 infection can spread into the
CNS, leading to HSV-1 encephalitis. [5] HSV-1 genomes are stably maintained in neurons in the absence of
virion production. [6] HSV re-activates in response to environmental and emotional stress (544). [7] Following
reactivation HSV-1 virions are transported down the axon (543). [8] HSV-1 reactivation can lead to HSV-1 lesions
and virion shedding (159).
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Figure 5: The HSV-1 lytic replication cycle.
[1] HSV-1 virions enter the cell by fusion of cellular membranes and the virion envelope. [2] The viral genome
un-coats from the virion capsid and enters the nucleus. [3-4] During latent infection, the viral genome is
circularised and maintained in a heterochromatic state such that lytic gene expression is silenced. LAT is the
only gene expressed. [5] During lytic infection, IE, E and L genes are expressed sequentially. [6] The virion
protein VP16 activates ICP0 transcription. ICP0 promotes expression of the other IE protein and promotes
cell survival. IE proteins activate E gene expression. [7] The E gene DNA Pol is responsible for replication
of the viral genome. [8-9] Other E proteins activate L gene expression. [10] L proteins include the structural
components used to synthesize nascent virion capsids. [11-12] De novo viral genomes are packaged into the
capsids and other L proteins orchestrate capsid envelopment and virion egress.
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Figure 6: Blocks to productive HSV-1 infection.
[1-2] HSV-1 virions enter the cell, the viral genome uncoats and is imported into the nucleus. [3] During
productive infection, the viral transcriptional transactivator VP16, brought into the cell within the virion particle,
translocates to the nucleus (545). [4] In neurons supporting latent infection, VP16 is retained in the cytoplasm.
This restriction provides the first block to productive viral infection, such that HSV-1 latency is established. [5]
During lytic infection, VP16 in the nucleus recruits the cellular factors oct-1 and HCF1 to the IE promoters [6],
and initiates IE gene transcription (546–548). HCF1 is a ubiquitous nuclear protein required for the progression
through the G1 phase of the cell cycle (545). [6] The VP16-oct-1-HCF1 complex binds a specific sequence,
TAATGARAT, within the viral promoter (549). [7] At this point in the viral replication cycle, E and L genes
are silenced by the cellular HDAC1-CoREST-REST complex, which binds to the viral genome (550). [8] ICP0,
an IE protein, promotes transcription of E and L genes by removing the HDAC1-CoREST-REST silencing
complex from the viral genome (550). [9] ICP0 contains a carboxyl-terminal domain sequence homologous to a
corresponding sequence near the N-terminus of CoREST. In the absence of functional ICP0, viral replication is
blocked following IE gene expression and prior to DNA replication. This is referred to as quiescent infection,
and can be reversed by addition of ICP0 or by activating ICP0 function. If this block is overcome, HDAC1 and
CoREST-REST are phosphorylated and exported from the nucleus by the viral proteins US3 and UL13
(545,551).
There are therefore 2 blocks to lytic replication that must be overcome during lytic replication that are overcome
by initiation of IE gene expression by VP16 and removal of the HDAC1-CoREST-REST silencing complex by
ICP0 [4 and 7].
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Figure 7: HIV-1 life cycle.
This figure is taken from Engelman et al (254). Following virion attachment and fusion (1,2), the viral capsid
uncoats (3). The RNA genome is reverse transcribed, forming the pre-integration complex (4). The pre-
integration complex is integrated into the host cell genome followed by viral transcription and translation (7,
8). Viral proteins assemble into the nascent viral capsid that buds from the cell (11-13)
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Figure 8: Vpx and SAMHD1.
[1] During entry the HIV-1 virion uncoats. [2] The dsRNA genome is reverse transcribed into the dsDNA
provirus using dNTPs within the cytoplasm. [3] In non-cycling cells SAMHD1 decreases the pool of dNTPs in
the cytoplasm. [4] Vpx binds SAMHD1 and promotes its degradation by recruiting the DDB1-CUL4A-DCAF1
E3 ubiquitin ligase complex. [5] SAMHD1 can also be deactivated by phosphorylation of cellular CDK1 in
cycling cells. [6] HIV-1 nucleic acids in the cytoplasm can be detected by cytoplasmic PRRs. [7] The HIV-1
provirus enters the nucleus, potentially facilitated by vpx, and integrates into the host genome.
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Figure 9: Monocyte derived macrophages.
120ml of blood was taken from healthy volunteers. The PBMC were extracted and the adherent monocytic
cells differentiated into macrophages by incubation with M-CSF for 6 days.
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Figure 10: Experimental model to investigate HSV-1 infection of macrophages.
Monocyte derived macrophages were exposed to sorbitol purified HSV-1 or UV-HSV-1. HSV-1 gene and protein
expression were assessed at various time points post infection.
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Figure 11: HSV-1 ICP0 and ICP4 protein expression in macrophages.
Macrophages were exposed to either HSV-1 or UV inactivated HSV-1. 6hpi, the cells were fixed, permeabilised
and stained for ICP0 (a) or ICP4 (b) expression. Representative images are shown for macrophages exposed to
250pfuvero/cell of HSV-1 or UV-HSV-1.
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Figure 12: HSV-1 IE protein expression in macrophages.
(a): Macrophages were exposed to either HSV-1 or UV inactivated HSV-1. The dose of HSV-1 ranged from
1 to 1000 pfuvero/cell. 6hpi, ICP4 expression was assessed by western blot. (b) Macrophages were infected
with UV-HSV-1 or HSV-1 expressing ICP0-YFP. 6hpi, the cells were detached from the plate by 45 minutes
incubation in 5% trypsin. The cells were fixed and ICP0-YFP positivity was determined using FACS. Each point
on the graph represents the total macrophages from one well of a 24 well plate. (c) and (d): Macrophages were
exposed to either HSV-1 or UV inactivated HSV-1. 6hpi, the cells were fixed, permeabilised and stained for
ICP0. ICP0+ (c) or ICP4+ (d) cells were counted using Metamorph image analysis software and the number
of positive cells were represented as a percentage of the total number of macrophages imaged (n 10,000) for
each condition. Each bar represents the mean of 3 donors, 6 replicate wells per donor. Error bars = SEM. The
1 way ANOVA p values are shown for the effect of HSV-1 dose on the percentage of cells expressing ICP0 or
ICP4.
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Figure 13: HSV-1 gB expression in macrophages.
(a) and (b): Macrophages were exposed to either HSV-1 or UV inactivated HSV-1. 6hpi, the cells were fixed,
permeabilised and stained for gB expression. (a): Representative images are shown for macrophages exposed
to 250pfuvero/cell of HSV-1 or UV-inactivated HSV-1. (b): gB
+ cells were counted using Metamorph image
analysis software and the number of positive cells were represented as a percentage of the total number of
macrophages imaged for each condition. Each bar represents the mean of 3 donors, 6 replicate wells per donor.
Error bars = SEM. One way ANOVA value is shown for the effect of HSV-1 dose on the percentage of cells
expressing gB. (c) to (e): Macrophages were exposed to HSV-1, total cell RNA was extracted, DNase treated
and reverse transcribed into cDNA. GAPDH and HSV-1 gB expression was determined by RT-qPCR. (c): The
Cτ values for the GAPDH expression levels. Each point represents the mean of 3 donors. Error bars = SEM.
(d): The Cτ values for the gB expression levels. Each point represents the mean of 3 donors. Error bars =
SEM. The 1 way ANOVA value is shown for the effect of HSV-1 dose on gB expression. (e): gB transcript
levels were normalized to GAPDH expression. Each bar represents the mean of 3 donors. Error bars = SEM. 2
way ANOVA p values are shown for the effect of dose or time on gB expression.
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Figure 14: HSV-1 E and L gene expression in macrophages.
(a) and (b): Macrophages were exposed to HSV-1 or UV-HSV-1. 2, 6 or 24hpi, total cell RNA was extracted,
DNase treated and reverse transcribed into cDNA. GAPDH and HSV-1 DNA pol (a) and HSV-1 LAT (b)
expression was determined by RT-qPCR. HSV-1 transcript levels were normalized to GAPDH expression. Each
bar represents the mean of 3 donors. Error bars = SEM. The 2 way ANOVA p values are shown for the effect
of HSV-1 dose or time on HSV-1 E gene expression. (c): Macrophages were exposed to HSV-1 or incubated
with LPS, in the presence or absence of an NF-κB inhibitor. After 2 hours, the cells were fixed, permeabilised
and stained for NF-κB. Image analysis software was used to calculate the ratio of cytoplasmic to nuclear NF-κB
in each imaged cell. Each data point represents the mean of 6 replicate wells per donor. The line represents
the mean of all three donors. Error bars = SEM. 2 way ANOVA p values are shown for the effect of HSV-1
or LPS on NF-κB activation, in the presence and absence of the inhibitor. (d): Macrophages were infected
with HSV-1 in the presence or absence of an NF-κB inhibitor. 24hpi, total cell RNA was extracted, DNase
treated and reverse transcribed into cDNA. GAPDH, HSV-1 DNA Pol and LAT expression were determined by
RT-qPCR. HSV-1 transcript levels were normalized to GAPDH expression. Each bar represents the mean of 3
donors. Error bars = SEM.
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Figure 15: Inhibiting HSV-1 infection of macrophages.
(a): Macrophages were exposed to HSV-1 treated with soluble heparin or infected with HSV-1 in the presence
of acyclovir. (b): Macrophages were exposed to HSV-1 or HSV-1 that had been incubated with heparin. 24hpi,
HSV-1 DNA Pol transcript levels were assessed by RT-qPCR and normalised to GAPDH expression. Each bar
represents the mean of 3 donors. (c): Macrophages were exposed to UV-HSV-1 or HSV-1 in the presence
or absence of acyclovir. 24hpi, gB transcript levels were assessed by RT-qPCR and normalised to GAPDH
expression. Each bar represents the mean of 3 donors. Error bars = SEM. 2 way ANOVA p values are shown
for the effect of dose or acyclovir on gB expression. (d): The efficiency of the DNase treatment was assessed
by performing qPCR for gB transcript on the DNase treated RNA samples. Each bar represents the mean of
>20 donors.
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Figure 16: HSV-1 induces a type I IFN response in macrophages.
(a): Macrophages were stimulated with either IFN-β, poly(I:C) or poly(dA:dT) for 6 hours. Cellular RNA
was harvested, purified and reverse transcribed into cDNA. RT-qPCR for IP10 and GAPDH transcript was
performed, and IP10 expression normalised to GAPDH expression. Each bar represents the mean of 3 donors.
Error bars = SEM. (b): Macrophages were infected with HSV-1 or exposed to UV-HSV-1. 2, 6 and 24hpi viral
and cellular RNA was harvested, purified and reverse transcribed into cDNA. RT-qPCR was performed for IP10
and GAPDH expression. IP10 transcript levels were normalised to GAPDH expression. Each bar represents the
mean of >3 donors. Error bars = SEM. (c) and (d): Macrophages were stimulated with recombinant IFN-β
(c) or infected with HSV-1 (d), in the presence or absence of an IFNR blocking antibody. After 6 (c) or 24
(d) hours, cellular RNA was harvested, purified and reverse transcribed into cDNA. A RT-qPCR for IP10 and
GAPDH transcript was performed, and IP10 expression normalised to GAPDH expression. Each bar represents
the mean of 3 donors. Error bars = SEM. 2 way ANOVA p values are shown for the effect of IFN-β dose
and IFNR blocking antibody on IP10 expression. (e): Macrophages were infected with HSV-1. 24hpi viral and
cellular RNA was harvested, purified and reverse transcribed into cDNA. RT-qPCR was performed for IFI16,
Mda5, RIG-I, IFN-β and GAPDH expression. ISG transcript levels were normalised to GAPDH expression. Each
bar represents the mean of 3 donors. Error bars = SEM. t-tests were performed for the difference between ISG
expression levels following exposure to either HSV-1 or UV-HSV-1. (f): Macrophages were infected with HSV-1
in the presence or absence of an NF-κB signalling inhibitor. 24hpi, viral and cellular RNA was harvested, purified
and reverse transcribed into cDNA. RT-qPCR was performed for IP10 and GAPDH expression. IP10 transcript
levels were normalised to GAPDH expression. Each bar represents the mean of 3 donors. Error bars = SEM. 2
way ANOVA p values are shown for the effect of HSV-1 dose on the NF-κB inhibitor on IP10 upregulation.
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Figure 17: Assessing cell death.
HSV-1 macrophages were infected with sorbitol purified HSV-1 or UV-HSV-1, in the presence or absence of
acyclovir. At various time points, virion release, cell viability and cell lysis was assessed. Cell viability was
determined by measuring the reduction capacity of a population of cells. Cell lysis was determined by assessing
LDH release.
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Figure 18: HSV-1 productively infects macrophages.
(a) and (b): The alamarBlue assay was used to assess the cell viability of populations of 293T cells of known
cell number (a) or macrophages were exposed to HSV-1 or UV-HSV-1, 24hpi, 48hpi or 72hpi (b). Each point
represents the mean of 3 experiments (a). Each bar represent the mean of 3 donors (b). Error bars = SEM.
t-tests were performed to assess the significance of the difference between viability of macrophages exposed to
5 and 50 or 500pfuvero/cell. (c): Macrophages were infected with HSV-1 or UV-HSV-1. 24, 48 and 72hpi, the
supernatents were collected and LDH levels assessed by ELISA. Cell lysis is represented as the LDH released from
a sample as a percentage of the LDH that would be released during lysis of the total macrophage population. 2
way ANOVA p values are shown for the effect of HSV-1 dose and time on macrophage death. (d): Macrophages
were infected with various doses of HSV-1. 1hpi, the cells were washed with PBS and the cell media replaced.
24hpi and 48hpi, the cell supernatents were collected and replaced with media. The supernatents were frozen,
thawed at a later date and titred by a vero cell plaque assay. Time 0 represents the input dose of HSV-1. Each
bar represents the mean of 3 donors, 3 replicates per donor. The 1 way ANOVA p-value is shown for the effect
of HSV-1 dose on virion production. (e) and (f): Macrophages were infected with HSV-1, exposed to HSV-1
in the presence of acyclovir or exposed to UV-HSV-1. 48hpi, the cell viability was assessed by the alamarBlue
assay (e), or the supernatents collected to assess cell lysis by LDH ELISA (f). Each bar represents the mean of
3 donors. Error bars = SEM. t-tests were performed.
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Figure 19: Nuclei counting.
Macrophages were infected with various doses of HSV-1, exposed to UV-HSV-1, (a), or infected with HSV-1
in the presence or absence of acyclovir (b). 24hpi, the cells were fixed, stained with DAPI and imaged using
an automated fluorescent microscope. For each well of the plate, 23 non-overlapping images were taken. The
number of nuclei per image were counted using image analysis software and added to give the total number of
nuclei per well. The total number of nuclei in an infected well of macrophages is represented as a percentage
of the total number of macrophages in a mock infected well. Each point represents the mean of 6 wells, from
1 donor (a). Each bar represents the mean of 3 donors. Error bars = SEM. The 1 way ANOVA p value shown
for the effect of HSV-1 dose on nuclei count.
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Figure 20: Caspase activation and membrane permeability in HSV-1 infected macrophages.
(a): Macrophages were infected with UV-HSV-1 or HSV-1 expressing ICP0-YFP. 6hpi the cells were detached
from the plate by incubation for 45 minutes in 5% trypsin. The cells were fixed, stained for Annexin V and
Annexin V positivity determined via FACS. Each bar represents the mean of 2 donors, 3 replicates per donor.
Error bars = SEM. 2 way ANOVA p values are shown for the effect of HSV-1 dose or UV inactivation on Annexin
staining. (b): HeLa cells were infected with HSV-1 or incubated with media containing either staurosporine
or a DMSO loading control. After 24 hours, the cells were incubated with media containing the fluorescently
labelled caspase inhibitor CaspACE-FITC for 20 minutes. The cells were then fixed, permeabilised, stained with
DAPI and imaged. (c) and (d): Macrophages were infected with HSV-1. At 6 or 24hpi, the cells were incubated
with media containing the fluorescently labelled caspase inhibitor CaspACE-FITC for 20 minutes. The cells were
then fixed, permeabilised, stained with DAPI, stained for ICP0 expression and imaged. (d): CaspACE+ cells
were scored using Metamorph image analysis software and the number of CaspACE+ cells was represented as a
percentage of the total number of macrophages imaged for each condition. Each bar represents the mean of 3
donors, 12 replicate wells per donor. Error bars = SEM. The 1 way ANOVA p values are shown for the effect
of HSV-1 dose on the precentage of caspACE positive cells at 6 and 24hpi.
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Figure 21: Analysis of nuclear morphology.
(a) and (b): HeLa cells were infected with HSV-1 or incubated with media containing either staurosporine
or a DMSO loading control. After 6 hours, the cells were then fixed, permeabilised, stained with DAPI and
imaged. Image analysis software was used to score the area and intensity of each nucleus (a). The scales on
this plot are arbitrary. The probability density of the average intensity and area of the nuclei were plotted using
R (b). (c): Macrophages were infected with HSV-1. After 24 hours, the cells were then fixed, permeabilised,
stained with DAPI and for ICP4 expression and imaged. Image analysis software was used to score each nucleus
for average ICP4 expression and nuclear area. (d): Macrophages were infected with HSV-1 or incubated with
media containing either staurosporine or a DMSO loading control. After 24 hours, the cells were then fixed,
permeabilised, stained with DAPI and imaged.
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Figure 22: Analysis of nuclear morphology in HSV-1 infected macrophages.
Macrophages were infected with HSV-1. 24hpi, the cells were fixed, permeabilised, stained with DAPI and
imaged. Image analysis software was used to score the area and intensity of each nucleus. These values were
expressed as a density plot using flowJo FACS analysis software (a). The percentage of nuclei in the top left
(b) and bottom left (c) quadrants were determined. 2 way ANOVA p values are shown for the effect of UV
inactivation of HSV-1 and dose on HSV-1 dependent nuclear morphology. Each bar represents the mean of 3
donors. Error bars = SEM.
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Pathway Inhibitor Action
pyroptosis Z-YVAD-FMK caspase-1 inhibitor
apoptosis Z-VAD-FMK pan-caspase inhibitor
necroptosis nec-1 RIP1 inhibitor
(b) (c)
(d) (e)
Figure 23: The mechanism of HSV-1 dependent cell death.
(a): Macrophages can die by apoptosis, pyroptosis or necroptosis. Apoptosis can be inhibited with a pan-
caspase inhibitor, Z-VAD. Pyroptosis can be inhibited with Y-VAD, a caspase-1 inhibitor. Necroptosis can be
inhibited with necrostatin-1 (nec-1). (b) and (d): Macrophages were infected with various doses of HSV-1 in
the presence of YVAD, ZVAD, nec-1 (b), an IFNR blocking antibody (d) or no inhibitor. 24hpi, the cells were
fixed, stained with DAPI and imaged using an automated fluorescent microscope. For each well of the plate,
23 non-overlapping images were taken. The number of nuclei per image were counted using image analysis
software and added to give the total number of nuclei per well. The total number of nuclei in an infected well
of macrophages is represented as a percentage of the total number of macrophages in a mock infected well.
Each bar represents the mean of 3 donors. Error bars = SEM. 2 way ANOVA p values are shown for the effect
of each inhibitor or HSV-1 dose on nuclei count. (c): Macrophages were exposed to various concentrations of
recombinant IFNβ for 24 hours, in the presence or absence of an IFNR blocking antibody. Macrophage viability
was assessed by the alamarBlue viability assay, and expressed as a percentage of mock stimulated cells in the
presence or absence of the IFNR blocking antibody. Each point represents the mean of 3 replicates from 1
donor. Error bars = SEM. 2 way ANOVA p values are shown for the effect of IFN-β or the IFNR antibody on
nuclei count. (e): Macrophages were infected with HSV-1 in the presence or absence of an NF-κB inhibitor.
24hpi, the cells were fixed, stained with DAPI and imaged using an automated fluorescent microscope. For each
well of the plate, 23 non-overlapping images were taken. The number of nuclei per image were counted using
image analysis software and added to give the total number of nuclei per well. The total number of nuclei in
an infected well of macrophages is represented as a percentage of the total number of macrophages in a mock
infected well. Each bar represents the mean of 3 donors.
Figures 138
Figure 24: An experimental model to investigate HIV-1/HSV-1 co-infection.
Macrophages were infected with single round HIV-1 and VSV pseudo-typed Vpx 6 days post isolation. After 6
days, the macrophages were infected with HSV-1. 24hpi, HSV-1 gene expression, HSV-1 dependent cell death
and ISG up-regulation were assessed.
Figures 139
(a) (b)
(c) (d)
Figure 25: The effect of HIV-1 on HSV-1 gene expression.
Macrophages were infected with single-round R9 BaL ∆env HIV-1. 6dpi, the macrophages were super-infected
with HSV-1. (a), (c) and (d): 24 hours after infection with HSV-1, total cellular RNA was extracted, DNase
treated and reverse-transcribed into cDNA. GAPDH and HIV-1 LTR (a), HSV-1 DNA Pol (c) and HSV-1 gB
(d) expression was assessed by RT-qPCR. Viral levels were normalised to GAPDH expression. (b): Co-infected
macrophages were fixed, permeabilsed and stained for ICP4. ICP4+ cells were scored using Metamorph image
analysis software and the number of ICP4+ cells was represented as a percentage of the total number of
macrophages imaged for each condition. In all the graphs, each bar represents the mean of at least 3 donors.
Error bars = SEM. 2 way p ANOVA values are shown for the effect of HSV-1 and HIV-1, with the Vpx control
excluded if necessary.
Figures 140
(a) (b)
(c) (d)
Figure 26: The effect of HIV-1 on HSV-1 productive infection.
Macrophages were infected with single-round HIV-1. 6dpi, the macrophages were super-infected with HSV-1.
(a): 48hpi the supernatent was collected and assessed for the presence of nascent virions by plaque assay on
vero cells. (b): 48hpi, the cells were assessed for viability by the AlamarBlue assay. Viability is represented as a
percentage of the viability of mock infected cells. (c): 48hpi, the supernatents were collected and LDH levels
assessed by ELISA. Cell lysis is represented as the LDH released from a sample as a percentage of the LDH
that would be released during lysis of the total macrophage population. (d): The nuclei in each condition were
counted using Metamorph image analysis software. The number of nuclei are represented as a percentage of
the number of nuclei in the mock infected macrophage cultures. In all of the graphs, each bar represents the
mean of at least 3 donors. Error bars = SEM. 2 way ANOVA p values are shown for the effect of HSV-1 and
HIV-1, with the Vpx control excluded if necessary.
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Figure 27: The effect of HIV-1 on HSV-1 dependent changes in nuclear morphology.
Macrophages were infected with single-round HIV-1 with Vpx, or Vpx only. 6dpi, the macrophages were super-
infected with various doses of HSV-1. 24 hours after infection with HSV-1, the macrophages were fixed, stained
with DAPI and imaged. The area and average intensity of each imaged nucleus was recorded using Metamorph
image analysis software. These values were represented on density scatter plots using FlowJo.
Figures 142
(a) (b)
Figure 28: Summary of the effect of HIV-1 on HSV-1 dependent changes in nuclear morphology.
Macrophages were infected with single-round HIV-1 with Vpx, or Vpx only. 6dpi, the macrophages were super-
infected with various doses of HSV-1. 24 hours after infection with HSV-1, the macrophages were fixed, stained
with DAPI and imaged. The area and average intensity of each imaged nucleus was recorded using Metamorph
image analysis software. These values were represented on density scatter plots using FlowJo. The percentage
of cells in the top left (b) and bottom left (a) quadrants are represented. In each graph, each bar represents
the mean of at least 3 donors. Error bars = SEM. 2 way ANOVA p values are shown for the effect of HSV-1
and HIV-1.
Figures 143
(a) (b)
Figure 29: The effect of HIV-1 on the type I IFN response to HSV-1 infection.
Macrophages were infected with single round HIV-1. 6dpi, the macrophages were super-infected with HSV-1. 24
hours after infection with HSV-1, total cellular RNA was extracted, DNase treated and reverse-transcribed into
cDNA. GAPDH and IP10 (a) and various ISGs (b) expression levels were assessed by RT-qPCR. ISG transcript
levels were normalised to GAPDH expression. In each graph, each bar represents the mean of at least 3 donors.
Error bars = SEM. 2 way ANOVA p values are shown for the effect of HSV-1 and HIV-1.
Figures 144
(a) (b)
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Figure 30: The effect of HSV-1 superinfection on HIV-1 infection.
(a) and (b): Macrophages were infected with single round HIV-1. 6dpi, the macrophages were super-infected
with HSV-1 (a) and/or stimulated with UV-HSV-1 (b). 24 hours after infection with HSV-1, total cellular
RNA was extracted, DNase treated and reverse-transcribed into cDNA. GAPDH and LTR expression levels were
assessed by RT-qPCR. LTR transcript levels were normalised to GAPDH expression. (c): Macrophages were
infected with full-length HIV-1. 6dpi, the macrophages were super-infected with HSV-1. 24 hours after infection
with HSV-1, total cellular RNA was extracted, DNase treated and reverse-transcribed into cDNA. GAPDH and
LTR expression levels were assessed by RT-qPCR. LTR transcript levels were normalised to GAPDH expression.
(d): Macrophages were infected with full-length HIV-1. 6 days post infection the macrophages were super-
infected with HSV-1 or stimulated with UV-HSV-1. After 24 hours, the supernatents were collected and HIV-1
virion release assessed by p24 ELISA. In all of the graphs, each bar represents the mean of at least 3 donors.
Error bars = SEM. 2 way ANOVA p values are shown for the effect of HSV-1, HIV-1 and IFN-β, with the Vpx
control excluded if necessary.
Figures 145
Figure 31: Organisation of the HSV-1 genome
The gene for the latency-associated transcripts (LATs) is diploid and located in the repeat regions flanking the
unique long (UL) sequence of the dsDNA genome. The minor (primary) latency associated transcript (mLAT) is
transcribed from the opposite strand to ICP0. The major LATs are introns of 1.5 kb and 2 kb that are spliced
from mLAT. IR, internal repeat; TR, terminal repeat; UL, unique long sequence; US , unique short sequence.
Figures 146
Figure 32: Model of HSV-1 latent infection of macrophages.
Experimental model to investigate whether HSV-1 establishes latency in macrophages. If this is the case we
would expect gB expression to decrease over time and LAT expression to persist and stabilise.
Figures 147
(a) (b)
(c)
Figure 33: Survival of HSV-1 infected macrophages.
(a): Macrophages were infected with various doses of HSV-1. At various time points post infection the cells
were fixed, stained with DAPI and imaged using an automated fluorescent microscope. For each well of the
plate, 23 non-overlapping images were taken. The number of nuclei per image was counted using image analysis
software and added to give the total number of nuclei per well. The total number of nuclei in an infected well
of macrophages is represented as a percentage of the total number of macrophages in a mock infected well.
Each bar represent the mean of 3 donors. Error bars = SEM. 2 way ANOVA p values are shown for the effect
of HSV-1 dose and time. (b) and (c): Macrophages were infected with HSV-1. 2, 7 and 14dpi, the cell viability
was assessed by the alamarBlue assay (b) or the supernatents collected to assess cell lysis by LDH ELISA (c).
Each bar represents the mean of 3 donors. Error bars = SEM. 2 way ANOVA p values are shown for the effect
of HSV-1 dose and time. NA = not analysed
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Figure 34: Transcription in HSV-1 infected macrophages over time.
(a) to (d): Macrophages were infected with HSV-1. At various time points post infection, total cell RNA was
extracted and GAPDH (c) and HSV-1 gB (a), LAT (b) or IP10 (d) expression determined by RT-qPCR. HSV-1
and IP10 transcript levels were normalised to GAPDH expression. Each bar represents the mean of 3 individual
donors. Error bars = SEM. 2 way ANOVA p values are shown for the effect of HSV-1 dose and time.
Figures 149
Figure 35: The effect of acyclovir on HSV-1 latency.
An experimental model to assess the effect of acyclovir on HSV-1 latency in macrophages. Macrophages were
infected with HSV-1 in the presence or absence of ACV. The effects of the drug on HSV-1 replicative infection
and latency were assessed by quantifying gB and LAT expression over time.
Figures 150
(a)
Figure 36: The effect of acyclovir on HSV-1 latency.
Macrophages were infected with HSV-1 in the presence or absence of acyclovir. At various time points post
infection, total cellular RNA was extracted, DNase treated and reverse-transcribed into cDNA. GAPDH, HSV-1
gB expression was assessed by RT-qPCR. Expression of viral genes were normalised to GAPDH expression. Each
bar represents the mean of 3 individual donors. Error bars = SEM. The 2 way ANOVA p values are shown for
the effect of acyclovir on HSV-1 gene expression, at a dose of both 2 and 20pfuvero/cell.
Figures 151
Figure 37: The effect of blocking the IFNR on HSV-1 latency.
Experimental Model. [1] HSV-1 infection of macrophages is replicative, and leads to cell death, virion release
and induction of a type I IFN response. [2] IFN-β release by HSV-1 infected macrophages induces a type I
IFN response in uninfected macrophages within 24 hours. Virion release from infected macrophages does not
occur until 48hpi. Secondary HSV-1 infection therefore occurs in already activated macrophages, potentially
restricting HSV-1 infection and leading to the establishment of latency. [3] HSV-1 replication and the HSV-1
dependent response can be inhibited using an NF-κB inhibitor or an IFNR blocking antibody respectively.
Figures 152
(a)
(b) (c)
Figure 38: The effect on HSV-1 latency of blocking the type I IFN receptor.
(a) to (c): Macrophages were infected with HSV-1 (2pfuvero/cell) in the presence or absence of an IFNR
blocking antibody. After 24 hours the antibody was removed. 24 hours or 1 week post infection, total cellular
RNA was extracted, DNase treated and reverse-transcribed into cDNA. GAPDH, IP10 (a), HSV-1 gB (b) and
LAT (c) expression were assessed by RT-qPCR. Expression of viral genes were normalised to GAPDH expression.
Each bar represents the mean of 3 individual donors. Error bars = SEM. The 2 way ANOVA p values are shown
for the effects of time and αIFNR.
Figures 153
Figure 39: An experimental model to assess whether HIV-1 can reactivate latent HSV-1.
Macrophages were infected with HSV-1. After 2 weeks, the macrophages that remained were exposed to HIV-1
or stimulated with LPS. After 24 hours, HSV-1 reactivation was assessed by measuring HSV-1 gB and DNA
pol expression and virion production.
Figures 154
(a) (b)
(c) (d)
Figure 40: HIV-1 reactivates latent HSV-1.
(a) and (b): Macrophages were infected with HSV-1. After 14 days the infected cells were super-infected with
HIV-1 or mock infected. At various time points post infection, total cellular RNA was extracted, DNase treated
and reverse-transcribed into cDNA. GAPDH and HSV-1 gB (a) or DNA pol (b) expression were assessed by
RT-qPCR. gB and DNA Pol transcript levels were normalised to GAPDH expression. (c): The supernatent
was collected from the infected macrophages and assessed by plaque assay on vero cells for the presence of
HSV-1 virions. Each bar represents the mean of 3 individual donors. Error bars = SEM. The 2 way ANOVA p
values are shown for the effect of HSV-1 dose or HIV-1 on HSV-1 gene expression levels at 2 weeks post HSV-1
infection, or the effect of time.
Figures 155
(a) (b)
(c) (d)
Figure 41: HIV-1 replication is required for HIV-1 dependent reactivation of latent HSV-1.
(a) to (d): Macrophages were infected with HSV-1. After 14 days the infected cells were exposed to HIV-1
or UV-HIV-1, LPS or mock infected. At various time points post infection, total cellular RNA was extracted,
DNase treated and reverse-transcribed into cDNA. GAPDH and IL-6 (a), HIV-1 LTR (b) and (c) and HSV-1
gB (d) expression were assessed by RT-qPCR. gB, LTR and IL-6 transcript levels were normalised to GAPDH
expression. Each bar represents the mean of 3 individual donors. Error bars = SEM. The 2 way ANOVA p values
are shown for the effect of UV-HIV-1 on HSV-1 gene expression, or LPS and HSV-1 on IL-6 gene expression.
Figures 156
(a) (b)
(c) (d)
Figure 42: A model for the establishment of latency in macrophages.
Figures 157
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Figures 158
Table 2: Interferons
Group Protein Genes Receptor Cell Source
Type I IFNα ifna1, ifna2,
ifna4, ifna5,
ifna6, ifna7, ifn8,
ifna10, ifna13,
ifna14, ifna16,
ifna17, ifna21
IFNAR1/IFNAR2 B cells, T cells, NK cells,
macrophages, endothelial
cells, pDC, MDDC, epithelial
cells, some neurons
IFNβ ifnb1
IFNκ  ifnk
IFNω ifnw1
Type II IFNγ ifng IFNGR1/IFNGR2 T cells, NK cells
Type III IFNλ il28a IFNLR1 macrophages, pDC,
monocyte derived dendritic
cells (MDDC), epithelial cells
IFNλ2 il28b
IFNλ3 il29
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Table 4: PRRs that detect HSV-1
HSV PAMP PRR Cell Response References
gB TLR2 HEK 293T Inflammatory cytokine
(428)
gH/gL αvβ3 integrin/TLR2 neurons, keratinocytes Type I IFN
(426)
gD unknown human PBMC, human
MDDC
Type I IFN
(616,616)
virion component mannose receptor human MDDC Type I IFN
(617)
cytoplasmic dsRNA RLRs murine macrophages,
MEFs
Type I IFN
(618)
Mda5 human macropahges Type I IFN
(191)
endosomal dsRNA TLR3 fibroblasts Type I IFN
(207)
endosomal DNA TLR9 mouse pDC Type I IFN
(619,620)
TLR9 human pDC Type I IFN
(621)
cytoplasmic DNA RNA Pol II/RIG-I murine macrophages Type I IFN
(622)
IFI16 murine macrophages Type I IFN
(49)
DAI murine macrophages,
L292 cells
Type I IFN
(47)
DHX36 human pDC cell line Type I IFN
(623)
cGAS THP1s Type I IFN
(143)
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Table 7: Viral factors involved in HIV-1 transcription
Viral factor Mechanism References
LTR A DNA sequence located at the 5’ end of the HIV-1 provirus.
Contains a canonical TATA box sequence followed by 2 NF-κB and 3
Sp1 binding sites. These constitute the core HIV-1 promoter to
which and cellular RNAPII, transcription factors and transactivators
are recruited.
(659–662)
TAR A 59 nucleotide stem-budge loop structured RNA element located at
the 5’ end of all HIV-1 transcripts. Functions as a transactivation
responsive region. Recruits tat and associated cellular factors to
promote completion of transcription initiated at the LTR promoter.
(663)
Tat An HIV-1 accessory protein that plays a highly specific role in the
recruitment of cellular transcription factors and enables elongation of
HIV-1 transcript by recruiting cellular cofactors, including the
P-TEFb complex, TFIID and TCERG1, to TAR.
(664–670)
Nef A HIV-1 accessory protein that indirectly increases LTR transcription
by positively regulating cellular transcription factors including NF-κB,
NF-AT and AP-1. Also up-regulates expression a cellular heat shock
protein, HSP40, that binds to the LTR promoter and enhances LTR
transcription.
(539,671)
Vpr An HIV-1 late gene product that mediates enhanced viral expression
by indirectly arresting the cell cylce in the G2/M phase, and directly
via transactivation of the LTR.
(672–674)
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Table 8: Cellular factors involved in HIV-1 transcription
Cellular factor References Additional information
P-TEF-b
(675)
A key regulator of the process controlling the processivity of RNA polymerase
II (676) that is recruited to the HIV-1 LTR by tat.
CDK9
(675)
A component of the P-TEFb that promotes elongation of the LTR transcript by
phosphorylating the Ser2 residue within the CTD of cellular RNAPII, leading to
the release of arrested RNA complexes in the 5’ regaion of the LTR.
TCERG1
(677,678)
A nuclear protein that promotes elongation of the LTR transcript by modulating
cellular RNAPII activity.
Sp1
(679–682)
A zinc finger transcription factor that binds to GC-rich motifs of many
promoters. Involved in many cellular processes, including cell differentiation,
apoptosis, immune responses and chromatin remodeling and is critical for in vivo
transcriptional regulation of HIV.
IRF-1/2
(679,680)
Member of the interferon regulatory transcription factor (IRF) family, activates
type I IFN and ISG transcription (683).
CREB-1/p300
(684–687)
Member of the leucine zipper family of DNA binding proteins. Binds the
cAMP-responsive element and induces transcription of genes in response to
stimulation of the cAMP pathway, for example by IL-6 or ICAM-1.
AP-1
(684,688)
Tat enables co-operation of NF-AT with this transcription factor.
NF-κB
(689,690)
A cellular transcription factor activated by a broad array of signalling events,
including type I IFN and cytokine receptor signalling.
NF-AT
(679,680,691)
A family of transcription regulators that plays a necessary role in T cell
activation via control of IL-2 gene activation. Bind specific sequences in the LTR
promoter and synergizes with NF-κB and tat to activate HIV-1 transcription.
HSF-1
(671)
A cellular heat shock protein that enhances LTR transcription directly, and
indirectly by enhancing Nef mediated upregulation of HSP40.
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Table 9: Lentivector plasmids for transfection
Lentivirus Plasmids
SIV3+ (Vpx) pMDG (VSV-G), SIV3+
∆Env R9 BaL pMDG (VSV-G), ∆Env R9 BaL, p8.9
R9 BaL R9 BaL
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Table 10: Function of glycoprotein B
Function Details/mechanism References
Evasion of the immune
system
HSV-1 infection of APC rapidly decreases CD1d surface expression and
inhibits recognition by CD1d restricted NKT cells. In CD1d expressing
HeLa cells gB interacts with CD1d in the ER and stably associates with
it during intracellular trafficking through the TGN, preventing the
recycling of CD1d back to the cell surface after endocytosis.
(388)
In a human melanoma cell line, gB binds MHC class II molecule HLA-DR
and diverts it into the endosomal pathway. (387)
A fusion protein during
virion entry
gB has structural homology to other viral fusion proteins, fusion
potential and along with gD, gH and gL, is one of the HSV-1
glycoproteins essential for virion entry.
(382–385)
Endosomal entry An acidic pH triggers conformational change and formation of the
oligometric state of gB pre-fusion forms. This is separable from its fusion
activity and is linked to gB’s ability to facilitate entry of the virion into
the cytosol from the low pH endosome.
(692–694)
Facilitates entry by
binding specific cell
surface molecules
PIRRα and MAG both function as gB receptors. gB O-glycans at
residues Thr53 and Thr480 associate with PIRRα. Mutation of these
residues decreases HSV-1 replication in the cornea of corneal inoculated
mice and decreases herpes stromal keratinitis and neuro-invasiveness -
suggesting that gB plays an important role in facilitating HSV-1 spread
and infectivity independent of other viral glycoproteins.
(695,696)
Endosomal location of
gB is with disease
The Thr-887 residue in the cytoplasmic tail of gB can be phosphorylated
by the HSV-1 protein US3 kinase, leading to decreased surface
expression and increased endosomal accumulation of gB. This is
associated with stromal keratitis and neuro-virulence in mouse models of
HSV-1 infection.
(697,698)
Cell-to-cell fusion gB expression on the cell surface facilitates cell fusion and the formation
of giant syncytia during HSV-1 infection. Trafficking of gB to the TGN
reduces cell fusion.
(699–701)
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Table 11: Functions of ICP0
Function Details/mechanism References
Activation of viral gene
expression
ICP0 transactivates IE, E and late gene expression through its E3
ligase function, dispersal of the HDAC1/CoREST/REST/LSD1
repressor complex and resultant acetylatation of histones at virus
promoters. ICP0 also recruits cyclin D3 to the sites of viral
replication in the nucleus.
(393,702–706)
Reactivation of latency ICP0 is necessary, and sufficient in combination with ICP4 and
VP16, for the efficient reactivation of HSV-1 in primary cultures
of latently infected TG cells. The ICP0 promoter can be activated
by stress induced cellular transcription factors.
(390–392,467,468)
Evasion of intrinisic cell
defences
Following entry of the viral genome into the nucleus, ND10 and
DNA damage proteins are recruited by the cellular ubiquitin
ligases RNF8 and RNF168, silencing the genome. ICP0 targets
RNF8 and RNF168 for degradation, enabling IE gene expression.
ICP0 also degrades the ND10 components PML and SP100.
(705,707–710)
Evasion of inflammatory
cytokine response
Inhibits NF-κB downstrean of TLR ligation, by mediating
translocation of USP7 from the nucleus to the cytoplasm. USP7
binds and deubiquitinates TRAF6 and IKKγ and thereby
termiates NF-κB signalling
(425)
Inhibits TNF-α mediated NF-κB activation by facilitating
degradation of p65 and preventing p50 nuclear translocation upon
TNF-α stimulation. This function of ICP0 requires the ring finger
domain.
(424)
Reduces the inflammatory cytokine response to TLR2 ligation by
decreasing the levels of MyD88 and TRIAP. (711)
Evasion of the type I IFN
response
During in vivo infection, ICP0 is necessary to prevent Stat-1
dependent type I IFN responses in HSV-1 infected mice. ICP0−
HSV-1 is hypersensitive to type I IFN treatment in tissue culture
(712–714)
ICP0 has been shown in combination with vhs, to inhibit IRF3
and IRF7 mediated induction of ISG transcription, via both Ring
Finger domain dependent and independent mechanisms.
(715–718)
Some observations indicate that ICP0 degrades the cytoplasmic
DNA sensor IFI16 and prevents nuclear IFI16 induction of IRF3
signalling. However, these results remain controversial.
(719)
Evasion of adaptive
immunity
Expression is sufficient to degrade CD38 in mature dendritic,
reducing the ability of these cells to stimulate T cells. (720–722)
Dismantling of the the
microtubule network
In a mechanism dependent upon the ring finger domain, ICP0
dismantles the microtublule network of the host cell late on during
HSV-1 infection, preparing the cell for virion synthesis and egress.
(723)
NK mediated cell lysis ICP0 expression is sufficient to increase the susceptibility of
HSV-1 infected cells to NK cell mediated lysis by upregulating cell
surface expression of the NCR ligands NKp30, NKp44, and
NKp46.
(724)
Virion entry ICP0 is contained in the tegument of HSV-1 capsids and is
necessary for the targeting of incoming capsids to the nucleus. (725)
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Table 12: LTR transcription activation by co-infecting pathogens and drugs
Drug/pathogen Mechanism Ref.
H
er
p
es
vi
ru
se
s
KSHV ORF50, an IE protein important for KSHV reactivation from
latency (437), interacts synergically with tat to enhance LTR transcription. (438,439)
HCMV CMV IE1/2 genes activate LTR transcription by an unknown mechanism.
(445,726,727)
VZV The IE4 protein trans-activates LTR transscription via a NF-κB
dependent mechanism. (441)
EBV The EBNA2 protein, important for the establishment and maintenance
of EBV latency in B cells (442), enhances LTR transcription vai a Sp1 and
NF-κB dependent mechanism.
(443)
HHV-6 HHV-6 co-infection of HIV-1 infected CD4+ T cells or human fetal
astrocytes enhances HIV-1 LTR transcription, via an NF-κB dependent
mechanism.
(444,445)
O
th
er
vi
ru
se
s
HBV HBX activates HIV-1 transcription by stimulating binding of C/EBPβ
and CREB1/2 to cis-regulatory elements in the HIV-1 LTR, such that
NF-κB and NF-AT are recruited.
(728)
AdV 13S E1A, activates LTR transcription via a p300 independent TBP
dependent mechanism. (729)
HCV Co-infection of wild-type virus with HIV-1 in hepatocytes enhances LTR
transcription and HIV-1 gene expression by an unknown mechanism,
although may involve interaction of the HCV protein NS3 with HIV-1
vpu.
(730,731)
B
a
ct
er
ia
Mycobacterium
tuberculosis
Rv1168C, a proline-proline-glutamic acid protein with unknown
function (732) that enhances LTR transcription by ligating TLR2 and
activating NF-κB signalling.
(446–448)
Intracellular bacteria Salmonella enteritidis, Yersinia enterocolitica, Legionella pneumophila
and Escherichia coli all increase HIV-1 transcription in macrophages,
although only Salmonella enteritidis also increases HIV-1 production.
LPS stimulates HIV-1 transcription in macrophages but not T cells.
(733)
Neisseria gonorrhoeae Increases HIV-1 transcription in Jurkat CD4 T cell and DC, via TLR2
ligation and NF-κB dependent mechanism. (449–451)
F
u
n
g
i Cryptococcus
neoformans and
Candida albicans
Increases HIV-1 transcription in human monocytes, via an NF-κB
dependent mechanism. (452)
P
ro
to
ci
st
s
Plasmodium falciparum Malarial antigens increase HIV-1 replication in T cells by activating LTR
transcription. (734)
Toxoplasma gondii Increases HIV-1 transcription in murine macrophages in vivo, via an
NF-κB dependent mechanism. (453)
Leishmania donovani The lipophosphoglycan surface molecule increases HIV-1 transcription in
myeloid cell lines, via a mechanism involving TNF-α. (735)
D
ru
g
s
Histone deacetylases
inhibitors
Drugs that cause global hyperacetylation and chromatin remodelling, for
example rapoxin (TPX) and trichostatin A (TSA) activate HIV-1
transcription in a NF-κB independent manner, involving the disruption
of nuc-1 binding of the HIV-1 promoter.
(257–259)
Retinoic acid Stimulates HIV-1 transcription in human neuronal SH-SY5Y cells in
cooperation with tat. (736)
Methamphetamines Neurotoxins and psychostimulants that enhances LTR transcription by
activating NF-κB signalling. (454)
1,25-Vitamin D Ligation of the VDR activates LTR transcription in HeLa, U937, and
Cos-1 cells, in an Sp1 and NF-κB independent mechanism. (737)
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Table 13: Transcription factors involved in both HSV-1 and HIV-1 transcription
Transcription factor Interaction with HSV-1
P-TEF-b Regulates transcription of IE gene promoters. P-TEF-b dependent transcription is
promoted by VP16 and inhibited by ICP22 (738) and by HSRG1 interaction with
Cyclin T2 (739).
Sp1 Required for IE and E transcription, phosphorylated and inactivated after TK
transcription (519).
CDK9 Required for HSV-1 transcription (740) and is regulated by ICP22 (741).
CBP-1/p300 ICP0 recruits CBP/p300 to nuclear structures away from the host chromatin (211).
CREB mediated transcription may be involved in reactivation from latency by
binding the LAT promoter (742).
CBP-1/p300 ICP0 recruits CBP/p300 to nuclear structures away from the host chromatin (211).
CREB mediated transcription may be involved in reactivation from latency by
binding the LAT promoter (742).
AP-1 ICP0 increases AP-1 transcription (743). AP-1 may be involved in reactivation from
latency by binding the LAT promoter (742).
NF-AT Activity blocked by HSV-1 infection (744).
NF-κB VP16 inhibits NF-κB activation to prevent induction of a type I IFN
response (426–428). ICP0 inhibits NF-κB activation in response to TNF-α (424).
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Table 14: Models and reactivation of HSV-1 latency
Model of latency Reactivation
In vivo animal models of infection Latently infected ganglion are removed from the animal
and cultivated in vitro (221,419,503,745–749)
UV irradiation eye inoculated with HSV-1 (750)
Transient hyperthermia or fever (751–753)
Iontophoresis of 6-hydroxydopamine (6-HD), followed by
topical instillation of 2% epinephrine to eye incoculated
with HSV-1 (754)
Sodium butyrate, a histone deacetylase inhibitor
Cell trauma (755)
Drug induced immune suppression (747,756–759)
Anti-apoptotic drugs, e.g. dexamethasone (221)
‘Social stress’ (760)
In vitro neuronal model: infection of PC12 cells in the
presence of ACV and/or NGF
Histone dacetylase inhibitors, e.g Trichostatin
A (256,486,487,490,503)
Spontaneous or following withdrawl of
ACV (256,486,487,503)
Removal of NGF (490)
Heat-stress (492)
Expression of ICP0, VP16, and ICP4 from adenovirus
vectors (487)
Stimulation with forskolin, an activator of cAMP
signalling (487)
HSV-2 quiescent infection of human embryonic lung
cells in vitro
HCMV super-infection and E gene expression (464)
Human keratinocytes layer containing a model of
quiescent neuron infection (PC12 cells)
UV irradiation (504)
Infection of primary superior cervical ganglion (SCG)
sympathetic neurons in the presence of ACV and NGF
Removal of ACV, addition of PI3K inhibitor during
continued NGF stimulation (761,762)
Infection of human embryo lung fibroblast or human or
rat fetal neurons in the presence of interferon and an
anti-HSV drug, e.g. acyclovir, followed by an increase in
incubation temperature after removal of the inhibitor
Cold shock (465,477,500–502)
Primary sympathetic neuronal cultures, grown in the
presence of NGF, infected with HSV
removal of NGF (502,763)
Infection of squamous epithelial cells cultured in a
three-dimensional organotypic tissue culture (764)
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Table 15: HIV-1 accessory proteins in the capsid
Accessory protein Functions
Vif Forms E3 ubiquitin ligase complex to direct degradation of APOBEC3
proteins (96–101)
Promotes ABOBEC3G virion exclusion in a degradation-independent manner,
potentially by recruiting the restriction factor into high molecular weight
RNA/protein masses that are unable to be encapsidated (432,512–514)
Auxiliary factor for HIV-1 reverse transcriptase, increasing its rate of association to
RNA or DNA templates (765,766)
Depletes the intracellular pool of ABOBEC3G by directly binding ABOBEC3G
mRNA and down-regulating its translation and stability (98,102,103)
Directly inhibits ABOBEC3G deamination activity by altering its processive DNA
scanning mechanism (104)
Inhibits cell-cycle progression at the G2 phase of the cell cycle by interfering with
Cdk1-CyclinB1 activation (524)
Drives cells out of G1 and into the S phase of the cell cycle (523)
Vpr Nuclear import of the preintegration complex (767)
Induces TLR4/MyD88-mediated IL-6 production and reactivates HIV-1 virion
production from latency (518)
Impairs dendritic cell maturation, macrophage maturation and T-cell
activation (768–770)
Impairment of mitochondrial functions and induction of apoptosis (521,522)
Induces G2 cell cycle arrest (525–527)
Enhances expression from unintegrated HIV-1 DNA (551)
Promotes NK cell-mediated killing (771,772)
Transactivation of HIV-1 LTR expression by interacting with Sp1 (517)
Increases hepatitis C virus RNA replication (520)
Nef Downmodulates expression of several immune molecules, including CD4, MHC-I,
MHC-II and C-C and C-X-C chemokine receptors (535,773,774)
Modulates cellular secretory pathways to facilitate HIV-1 virion egress (775)
Increases the efficiency of HIV-1 RT and facilitates proviral synthesis (776,777)
Regulates viral protease activity (778)
Alters macrophage function, for example by regulating the release of superoxide
anions and inducing the secretion of chemotactic factors (779,780)
Protects macrophages from HIV-1- and stress induced apoptosis (529–531)
Activates AP-1, NFκB, STAT1 and STAT3 transcription factors (529,539–541)
suppresses argonaute-2 function and causes large-scale dysregulation of cellular
miRNAs (781,782)
Prevents apoptosis of HIV-1-infected T cells through either interference with
Fas/TNFαreceptor death-signalling pathways by inhibiting apoptosis
signal-regulating kinase 1 (ASK-1), or by inactivating of the pro-apoptotic Bad
protein (532–535)
Promotes KSHV latency via regulation of cellular miRNA (783)
